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A B S T R A C T
Background
Incontinence-associated dermatitis (IAD) is one of the most common skin problems in adults who are incontinent for urine, stool, or
both. In practice, products and procedures are the same for both prevention and treatment of IAD.
Objectives
The objective of this review was to assess the effectiveness of various products and procedures to prevent
and treat incontinence-associated dermatitis in adults.
Search methods
We searched the Cochrane Incontinence Group Specialised Trials Register, which contains trials identified from the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, CINAHL, Clini-
calTrials.gov, WHO ICTRP and handsearching of journals and conference proceedings (searched 28 September 2016). Additionally
we searched other electronic databases: CENTRAL(2015, Issue 4), MEDLINE (January 1946 to May Week 3 2015), MEDLINE In-
Process (inception to 26 May 2015), CINAHL(December 1981 to 28 May 2015), Web of Science (WoS; inception to 28 May 2015)
and handsearched conference proceedings (to June 2015) and the reference lists of relevant articles, and contacted authors and experts
in the field.
Selection criteria
We selected randomised controlled trials (RCTs) and quasi-RCTs, performed in any healthcare setting, with included participants over
18 years of age, with or without IAD. We included trials comparing the (cost) effectiveness of topical skin care products such as skin
cleansers, moisturisers, and skin protectants of different compositions and skin care procedures aiming to prevent and treat IAD.
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Data collection and analysis
Two review authors independently screened titles, abstracts and full-texts, extracted data, and assessed the risk of bias of the included
trials.
Main results
We included 13 trials with 1316 participants in a qualitative synthesis. Participants were incontinent for urine, stool, or both, and were
residents in a nursing home or were hospitalised.
Eleven trials had a small sample size and short follow-up periods. .The overall risk of bias in the included studies was high. The data
were not suitable for meta-analysis due to heterogeneity in participant population, skin care products, skin care procedures, outcomes,
and measurement tools.
Nine trials compared different topical skin care products, including a combination of products. Two trials tested a structured skin
care procedure. One trial compared topical skin care products alongside frequencies of application. One trial compared frequencies of
application of topical skin care products.
We found evidence in two trials, being of low and moderate quality, that soap and water performed poorly in the prevention and
treatment of IAD (primary outcomes of this review). The first trial indicated that the use of a skin cleanser might be more effective
than the use of soap and water (risk ratio (RR) 0.39, 95% confidence interval (CI) 0.17 to 0.87; low quality evidence). The second
trial indicated that a structured skin care procedure, being a washcloth with cleansing, moisturising, and protecting properties, might
be more effective than soap and water (RR 0.31, 95% CI 0.12 to 0.79; moderate quality evidence). Findings from the other trials,
all being of low to very low quality, suggest that applying a leave-on product (moisturiser, skin protectant, or a combination) might
be more effective than not applying a leave-on product. No trial reported on the third primary outcome ’number of participants not
satisfied with treatment’ or on adverse effects.
Authors’ conclusions
Little evidence, of very low tomoderate quality, exists on the effects of interventions for preventing and treating IAD in adults. Soap and
water performed poorly in the prevention and treatment of IAD. Application of leave-on products (moisturisers, skin protectants, or
a combination) and avoiding soap seems to be more effective than withholding these products. The performance of leave-on products
depends on the combination of ingredients, the overall formulation and the usage (e.g. amount applied). High quality confirmatory
trials using standardised, and comparable prevention and treatment regimens in different settings/regions are required. Furthermore,
to increase the comparability of trial results, we recommend the development of a core outcome set, including validated measurement
tools. The evidence in this review is current up to 28 September 2016.
P L A I N L A N G U A G E S U M M A R Y
Interventions for preventing and treating incontinence-associated dermatitis in adults
Background
Incontinence-associated dermatitis (IAD) is an inflammation of the skin due to contact with urine or stool. IAD occurs in people with
involuntary loss of urine or stool (incontinence). The main symptom of IAD is skin redness. In addition, bullae, skin lesions, and
skin infection may occur. IAD affects one to five in ten incontinent adults and is a risk factor for pressure-related skin problems. To
prevent and treat IAD, skin cleansing and skin care products are recommended. Many skin care products and procedures are available.
The skin care products can be divided into cleansers, moisturisers, and protectants which may be combined (for example, a cleanser/
moisturiser). In practice, products and procedures are the same for both prevention and treatment.
Review question
This review clarified the effect of various skin care products and procedures to prevent and treat IAD.
Study characteristics
We included randomised controlled trials which compared skin care products, procedures, methods for using skin care products and
frequencies of using a skin care product. The participants had to be over 18 years of age.
Key results
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We found thirteen, mostly small, trials, involving 1316 participants. All participants were incontinent for urine, stool, or both and lived
in nursing homes or were hospitalised. The trials tested skin care products, procedures, and frequencies of using a skin care product.
Two trials showed that soap and water performed poorly in the prevention and treatment of IAD. A skin cleanser or a washcloth with
cleansing, moisturising and protecting properties may be more effective than soap and water. The findings from the other trials suggest
that using a skin care product is more effective than withholding a skin care product. We found no evidence that one skin care product
performed better than another. The trials did not report on adverse effects.
Quality of evidence
The quality of the evidence was low. Eleven trials had small numbers of participants and were of short duration. The overall risk of bias
was high.
Authors conclusions
The trials included in this review tested skin care products, procedures and frequencies of using a skin care product. Very limited
evidence exists on the effects of interventions for preventing and treating IAD in adults. Larger, long-term and well performed trials
are required. Furthermore, we recommend the development of a list of outcomes which are important for patients and will guide
researchers in their study. This list should include well developed tools to measure the items in order to obtain accurate results.
How up-to-date is this review?
The review authors searched for studies that had been published up to 28 September 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any topical skin care product versus another topical skin care product
Patient or population: adults with incont inence
Setting: hospitals and nursing homes
Intervention: any topical skin care product
Comparison: another topical skin care product
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with skin care
product B
Risk with skin care
product A
Number of participants
with IAD (residual, i.e.
not healed)
(1) No-rinse
skin cleanser and skin
cream (A) versus soap
and water and lot ion (B)
Study populat ion RR 0.36
(0.08 to 1.68)
31
(1 RCT)
⊕©©©
VERY LOW
Based on one small
study.
308 per 1.000 111 per 1.000
(25 to 517)
Number of participants
with IAD (residual, i.e.
not healed)
(2) Desit in (A) versus
Calmosept ine (B)
Study populat ion RR 1.16
(1.00 to 1.34)
142
(1 RCT)
⊕⊕⊕©
MODERATE
Basd on one study and
sponsored by industry.
783 per 1.000 908 per 1.000
(783 to 1000)
Number of participants
with IAD (new)
(1) Skin cleanser (A)
versus soap and water
(B)
Study populat ion RR 0.39
(0.17 to 0.87)
65
(1 RCT)
⊕⊕©©
LOW
Based on one small
study and sponsored by
industry.
469 per 1.000 183 per 1.000
(80 to 408)
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Number of participants
with IAD (new)
(2) Sudocrem (A) ver-
sus zinc oxide cream
(B)
Study populat ion RR 1.03
(0.20 to 5.19)
27
(1 RCT)
⊕⊕©©
LOW
Based on one small
study.
182 per 1.000 187 per 1.000
(36 to 944)
Number of participants
with IAD (new)
(3)
No-rinse skin cleanser/
moisturiser and a f ilm-
form ing skin product
(A) versus cleansing/
moisturising/ skin pro-
tect ing washcloth (B)
Study populat ion RR 0.83
(0.35 to 1.95)
64
(1 RCT)
⊕⊕©©
LOW
Based on one small
study. Corresponding
author was member of
the company who deliv-
ered the study products
273 per 1.000 226 per 1.000
(95 to 532)
Number of participants
not satisfied with treat-
ment
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to IAD
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to skin
care product or proce-
dure
No data for this out-
come were reported in
the eligible studies
Adverse reaction due
to the skin care product
or procedure, e.g. skin
irritation, rash, itching,
allergic
reaction
No data for this out-
come were reported in
the eligible studies
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Incremental cost-ef-
fectiveness
Zinc oxide oil (A) versus
f ilm-form ing skin prod-
uct (B)
39
(1 RCT)
⊕©©©
VERY LOW
One small study re-
ported data on this
outcome. The results
on cost-ef fect iveness
were on average in
favour of the f ilm-form-
ing skin product. Due
to lim ited report ing of
stat ist ical data, it is un-
clear whether these dif -
ferences in cost-ef fec-
t iveness are real
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IAD: incont inence-associated dermatit is; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
Incontinence is defined as the complaint of any involuntary loss
of urine (urine incontinence) or faecal material (faecal inconti-
nence) or both (double incontinence) (ISC 2009). Incontinence
is a widespread problem in all healthcare settings (Du Moulin
2008;Macmillan 2004). Figures from studies on the prevalence of
urinary/faecal incontinence vary, mainly attributable to the pop-
ulation type and the study protocol used. With prevalence esti-
mates between 10% and 15% for faecal incontinence measured in
community-dwelling adults (Macmillan 2004; Shamliyan 2007),
and up to 46% for urinary incontinence measured in older, home
care patients (Du Moulin 2008), it is clear that incontinence care
is an important task for clinicians, patients, and their carers. In-
continence can lead to numerous complications. One of the most
common complications is perineal skin breakdown (Gray 2010;
Langemo 2011).
Incontinence-associated dermatitis
We can define incontinence-associated dermatitis (IAD) as ery-
thema and oedema of the surface of the skin, sometimes accom-
panied by bullae with serous exudates, erosion, or secondary cu-
taneous infection. Skin exposed to moisture, such as faecal or uri-
nary incontinence, is susceptible to the development of IAD. Gray
2007 defined IAD as a skin inflammation manifested as redness
with or without blistering, erosion, or loss of the skin barrier func-
tion that occurs as a consequence of chronic or repeated exposure
of the skin to urine or faecal matter. IAD is the result of top-down
damage to the skin due to:
• tissue intolerance (e.g. age, nutrition);
• an affected perineal environment (e.g. due to incontinence);
and
• problems with toileting ability (e.g. restraints) (Beeckman
2009).
The most important aetiologic factors are urinary, faecal, and
double incontinence (Beeckman 2014). Faecal incontinence has
been identified as a particularly high risk factor for the develop-
ment of IAD, with liquid faecal matter as the most severe irritant
(Beeckman 2009).
Traditionally, IAD has received little attention as a distinct skin
disorder, and it is regularly confused with Category/Stage I and II
pressure ulcers (Beeckman 2010; Beeckman 2014). The clinical
presentation of IAD ranges from erythema (with or without loss
of skin) to cutaneous infections (such as candidiasis) (Beeckman
2007). IAD is often associated with redness, rash, or vesiculation
(Gray 2007). Although the lesions are superficial, they are likely
to become slightly deeper when an infection occurs. In contrast,
the clinical signs of pressure ulcers range from non-blanchable ery-
thema of the intact skin, over partial/full thickness skin loss, to
tissue destruction involving skin, subcutaneous fat, muscle, and
bone (NPUAP 2014). A recent systematic review and meta-anal-
ysis by Beeckman 2014 confirmed incontinence (and moisture in
general) and IAD as an important risk factor for pressure ulcer
development.
Prevalence
Studies report prevalence figures of IAD between 5.6% to 50.0%,
with incidence rates between 3.4% and 25.0%, depending on the
type of setting and population studied (Gray 2007). Most epi-
demiological studies were performed in small sample, single-cen-
tre, and long-term care settings (Gray 2012). A study on the preva-
lence of IAD among hospitalised acute care patients in the United
States (n = 976) reported a prevalence of 27% (Junkin 2007). A
study using a large sample (n = 3713) of incontinent participants
reported an overall IAD prevalence across different healthcare set-
tings in two European countries of 6.1% (Kottner 2014). Approx-
imately one-third of people with faecal incontinence develop IAD
(Gray 2002). Incontinence, and subsequent skin breakdown, have
a considerable effect on patients‘ physical and psychological well-
being (Newman 2007; Sibbald 2003).
Aetiology
The aetiology of IAD is complex and related to both chem-
ical and physical irritation of the skin (Beeckman 2009).
Ananthapadmanabhan 2004 demonstrated that a rise in pH
(caused by urine and faeces) increases stratum corneum swelling
and alterations in lipid rigidity, thus increasing the permeability of
the skin and reducing the barrier function. Furthermore, a more
alkaline pH increases the risk of bacterial colonisation, and thus
cutaneous infections. Friction (physical irritation) increases when
the skin rubs over clothing, diapers/pads, and bed or chair surfaces.
The combination of chemical and physical irritation results in a
weakened skin. If these mechanisms affect the integrity of the skin
recurrently, IAD and further skin breakdown are likely to develop
(Beeckman 2009).
To date, there has been a lack of rigorously performed research ad-
dressing the effectiveness of different skin care regimens to prevent
or treat IAD. A number of studies compared the use and effects
of different types of skin regimens, but design weaknesses seem
to be common. Tentative evidence indicates that key prevention
recommendations include structured skin care regimens including
gentle cleansing, moisturising, and the application of skin protec-
tants or moisture barriers.
Description of the intervention
Current prevention of IAD consists of skin care interventions such
as skin cleansing, moisturising/skin conditioning, and the appli-
cation of skin protectants/barriers. Treatment includes protecting
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the skin from further exposure to irritants, establishing a healing
environment, and eradicating skin infections. A plethora of over-
the-counter and prescribed products for cleansing, moisturising,
and protecting (creams, ointments, pastes, film layers, etc.) as well
as procedures to apply the products (for example, frequency and
method of application) are currently available. The same products
are used for patients with and without IAD. Topical antibiotics
and antimycotics are additionally used to eradicate skin infections.
How the intervention might work
We considered three main interventions (cleansing, moisturising,
protection) using topical skin care products in this Cochrane Re-
view. We also investigated different procedures for their use, such
as frequency or method of application.
Cleansing
Skin cleansing aims to remove dirt, debris, and micro-organisms
on the skin surface, usually using water alone or in combination
with skin cleansers.
Moisturising
Skin moisturising aims to repair or augment the skin’s barrier,
retain and/or increase its water content, reduce transepidermal
water loss, and restore or improve the intercellular lipid structure.
Protectants and barriers
The primary purpose of a skin protectant is to prevent skin break-
down by providing an impermeable or semipermeable barrier on
the skin, thus preventing or reducing the penetration of water and
chemical and biological irritants found in stool and urine.
Why it is important to do this review
A wide range of topical skin care products and procedures are
currently used in practice. Despite their widespread use, little is
known about their efficacy and effectiveness. We conducted this
review to clarify the effects of various products and skin care pro-
tocols to prevent and treat IAD in adults.
O B J E C T I V E S
The objective of this review was to assess the effectiveness of var-
ious products and procedures to prevent and treat incontinence-
associated dermatitis in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs and quasi-RCTs if one arm of the trial in-
cluded a structured and well-defined procedure (including a stan-
dard frequency, method, and product selection) or a skin care
product used to prevent or treat incontinence-associated dermati-
tis (IAD). We compared these with other structured skin care pro-
cedures or unstructured (not standardised) procedures or other
products, methods, or frequencies used to prevent or treat IAD.
Types of participants
Studies involving male or female participants, or both, over 18
years of age, in any healthcare setting, with or without IAD (de-
fined as erythema and oedema of the surface of the skin, some-
times accompanied by bullae with serous exudates, erosion, or sec-
ondary cutaneous infection) were eligible for inclusion.
Types of interventions
We included trials of topical skin care products such as skin
cleansers, moisturisers, and skin protectants of different composi-
tions and skin care procedures aiming to prevent or treat IAD in
this Cochrane Review. We examined the following comparisons.
1. Any topical skin care product versus another topical skin
care product.
i) Cleansing products
ii) Moisturising products
iii) Protectants and barriers
2. Any skin care procedure (method or frequency of
application) versus any unstructured skin care procedure.
3. Any method of application of a topical skin care product
versus another method of application of the topical skin care
product.
4. Any frequency of application of a topical skin care product
versus another frequency of application of the topical skin care
product.
Types of outcome measures
Primary outcomes
1. Number of participants with incontinence-associated
dermatitis (IAD) (residual, i.e. not healed)
2. Number of participants with IAD (new) (only suitable to
evaluate interventions for preventing IAD)
3. Number of participants not satisfied with treatment
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Secondary outcomes
1. Participants’ observations
i) Number of participants with pain due to IAD
ii) Number of participants with pain due to skin care
product or procedure
2. Quantification of symptoms (objective measures)
i) Surface affected by IAD (measurement of size of
lesion)
3. Clinicians’ observations
i) Number of participants with IAD not improved (only
suitable to evaluate interventions for treating IAD)
ii) Number of participants not complying/discontinuing
treatment (acceptability and tolerance)
4. Quality of life
i) Condition-specific
ii) Generic (e.g. SF-36, EQ-5D, Manchester Short
Assessment of Quality of Life)
iii) Psychosocial
5. Economic data
i) Cost of products
ii) Staff time
iii) Incremental cost-effectiveness
6. Adverse effects (of the interventions)
i) Adverse reaction due to the skin care product or
procedure, e.g. skin irritation, rash, itching, allergic reaction
ii) Normal flora disruption
iii) Toxicity
7. Other outcomes (non-prespecified outcomes judged
important when performing the review)
i) IAD severity
ii) Number of participants with IAD completely healed
iii) Number of participants with bacterial or fungal
infection
Search methods for identification of studies
We undertook a two-step search strategy to identify relevant lit-
erature. Firstly, we searched electronic databases. Secondly, we
searched other sources, such as conference proceedings. We im-
posed no restrictions, such as language or publication status, on
the searches.
Electronic searches
This review drew on the search strategy developed for the
Cochrane Incontinence Group. We identified relevant trials from
the Cochrane Incontinence Group Specialised Trials Register. For
more details of the search methods used to build the Specialised
Register, please see the Group’s module in the Cochrane Library.
The register contains trials identified from the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, MED-
LINE In-Process, MEDLINE Epub Ahead of Print, CINAHL,
ClinicalTrials.gov,WorldHealthOrganisation International Clin-
ical Trials Registry Platform (WHO ICTRP), and handsearching
of journals and conference proceedings. Many of the trials in the
Cochrane Incontinence Group Specialised Register are also con-
tained in CENTRAL.
The terms used to search the Cochrane Incontinence Group Spe-
cialised Register are given in Appendix 1. The date of the last
search was 28 September 2016.
Additionally, as the condition can be very poorly described, espe-
cially in the older literature, we searched the following electronic
databases.
• CENTRAL on OvidSP 2015, Issue 4 was searched on 27
May 2015. The search strategy is given in Appendix 2.
• MEDLINE on OvidSP (from January 1946 to May Week
3, 2015) was searched on 27 May 2015. The search strategy is
given in Appendix 2.
• MEDLINE In-Process on OvidSP (covering 26 May 2015)
was searched on 27 May 2015. The search strategy is given in
Appendix 2.
• Cumulative Index for Nursing and Allied Health
(CINAHL), was searched through the EBSCO Interface, from
inception (December 1981) to the most recent version available
(27 May 2015) on 28 May 2015. The search strategy is given in
Appendix 3.
• Web of Science (WoS) (on Web of Knowledge) was
searched from inception of the constituent databases to the most
recent available versions, on 28 May 2015. The search was
limited to the WoS Core Collection. The search strategy is given
in Appendix 4.
Searching other resources
The review authors contacted authors of trials included in this
Cochrane Review and asked them if they knew of any other RCTs
possibly relevant for this review. We also contacted experts in the
field to identify additional trials.
We handsearched the following conference proceedings: Euro-
pean Pressure Ulcer Advisory Panel (2000 to July 2015), Euro-
pean Wound Management Association (2001 to July 2015), and
Wound, Ostomy and Continence Nurses Society (1994 to July
2015).
We screened the reference lists of all included trials and other
relevant literature reviews to identify additional papers.
Data collection and analysis
Selection of studies
Two review authors (NVD and KVDB) independently screened
titles and abstracts of all identified records. They retrieved and
further checked for inclusion the full text of all potentially relevant
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records. NVD and KVDB sought the advice of a third review
author (AVL) to resolve disagreements and documented reasons
for exclusion of the records read in full.
Data extraction and management
Two review authors (SW and JK) independently extracted data
from the included trials. We developed a standardised form to
use in this review. We pilot-tested the extraction form to identify
whether we should collect additional data or improve the form.
The standardised form included the following data to be extracted:
aim, design, setting, sample characteristics, description of inter-
vention and comparison, outcome, and limitations. If necessary,
we contacted the authors of the included studies to request addi-
tional information.
Assessment of risk of bias in included studies
We evaluated the methodological quality of all included articles
using Cochrane’s ’Risk of bias’ tool. This includes the following:
selection bias, performance bias, detection bias, attrition bias, re-
porting bias, and other bias (bias not covered elsewhere). We as-
signed each domain a judgement of ‘low risk’, ‘high risk’, or ‘un-
clear risk’ of bias, whichwe interpreted in accordance withChapter
8 of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). Five review authors (MG, LS, JK, SW, DDM)
independently assessed the risk of bias. If necessary, these authors
sought the advice of DB to resolve disagreements.
Measures of treatment effect
We calculated risk ratios (RRs) with a 95% confidence interval
(CI) for binary outcomes andmean differences (MDs) with a 95%
CI for continuous data.
Unit of analysis issues
The unit of analysis of RCTs and quasi-RCTs were individual
participants. If appropriate, we used the following choices for other
designs.
• Cross-over design: we planned to use the first treatment
period.
• Cluster-RCTs: we took into account the clustering effect.
Dealing with missing data
The review authors contacted the authors of studies with missing
data to request additional information. We used the intention-
to-treat analysis (defined as analysed in the group to which the
participants were randomised whether or not they received the
intervention) and available case analysis (that is data as reported by
trialists without imputation for missing data).If data were missing
to the extent that we could not include the trial in the analysis, we
presented the results in a narrative way. If there was evidence of
differential dropout, we gave consideration to imputation of the
missing data.
Assessment of heterogeneity
Weplanned to combine the studies in ameta-analysis if the clinical
and methodological heterogeneity were acceptable.We judged the
clinical heterogeneity based on population and intervention type.
Due to large clinical and methodological heterogeneity, the data
were not suitable for meta-analysis.
We planned to assess the statistical heterogeneity using the Chi²
test at a significance level of 0.10 and calculate the I² statistic to
quantify the heterogeneity. We would interpret the I² in accor-
dance with Chapter 9 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011), and we would explore the
source of heterogeneity using subgroup and sensitivity analysis.
However, we did not perform a Chi² test nor calculated the I²
statistic because a meta-analysis was not suitable.
Assessment of reporting biases
A comprehensive search for eligible studies and alertness for du-
plication of data minimised the potential impact of publication
and reporting bias. It was not possible to perform a funnel plot
to assess reporting bias because of non-comparable designs and
outcomes.
Data synthesis
We entered data of all the trials in the software program Review
Manager (RevMan 2014).
We planned to use a fixed-effect model when pooling the data,
except for studies with an I² equal to or greater than 75%, in which
case we would use a random-effects model. However, due to large
clinical and methodological heterogeneity, it was not suitable to
pool data. We presented the results in a narrative way.
We rated the quality of the evidence by using the software program
GRADEpro (GRADEpro GDT 2014). We assessed the relevance
of the effect of the interventions based on a judgment of each
participant-important outcome separately. GRADE allowed us to
assess the quality of the body of evidence by taking into account
five considerations: study limitations, consistency of effect, im-
precision, indirectness, and publication bias (Guyatt 2011).The
GRADE working group strongly recommends including up to
seven potentially participant-important outcomes in a systematic
review (Guyatt 2011). Based on discussion within the research
group, the review authors selected the following potentially im-
portant participant outcomes.
1. Number of participants with IAD (residual).
2. Number of participants with IAD (new).
3. Number of participants not satisfied with treatment.
4. Number of participants with pain due to IAD.
5. Number of participants with pain due to skin care product
or procedure.
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6. Adverse reaction due to the skin care product or procedure,
e.g. skin irritation, rash, itching, allergic reaction.
7. Incremental cost-effectiveness.
We presented participant-important outcomes in Summary of
findings for the main comparison and Summary of findings 2.
R E S U L T S
Description of studies
Results of the search
The literature search produced 4089 records, from which we fur-
ther assessed 40 full-text articles for eligibility. Fourteen (quasi)
randomised trials met the inclusion criteria for this review. One
of these studies is awaiting classification, as Japanese transla-
tion is needed (Kajii 2005; Characteristics of studies awaiting
classification). Additionally there were two ongoing studies (
NCT02570139 2015; NCT02690753 2016). The PRISMA di-
agram in Figure 1 presents the flow of the literature search.
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Figure 1. PRISMA study flow diagram.
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Included studies
We included 13 (quasi-)RCTs in the qualitative synthesis (see
Characteristics of included studies). The total number of partici-
pants included in the analyses was 1295.
Design
Eleven trials had a parallel group design. One trial had a cluster
design (Beeckman 2011).One trial had a cross-over designwithout
a washout period between treatments (Byers 1995).
Settings
Nine trials were performed at single centres. Of these, six were
located in the United States, one in the Philippines, one in China,
and one in theNetherlands. Five of these single-centre studies were
conducted in hospitals and four in nursing homes.
One trial was conducted on geriatric wards of hospitals from one
health service trust in the United Kingdom.
Of the three remaining trials, one was conducted in 11 nursing
homes in Belgium, one in 22 nursing homes in the Netherlands,
and one in five long-term care centres in the United States.
Participants
The mean age of the participants varied between 59 and 89 years
across all studies. In more than half of the trials (7/13), the mean
age was over 80 years. In the Lewis-Byers 2002 trial, conducted in
a nursing home, the participants were between 41 and 105 years
old. Two other trials, of which one was conducted in a hospital
and one in a nursing home, did not report data on participants’
age (Dieter 2006; Kennedy 1996).
Most of the trials (n = 10) recruited participants with all types of
incontinence. In one trial, participants with faecal incontinence
were included (Wang 2011). In another trial, only female partic-
ipants with both urinary and faecal incontinence were included
(Byers 1995). In a last trial, the type of incontinence was not re-
ported (Anthony 1987).
In six trials, more than half of the participants showed neither red-
ness nor skin erosion. Two trials included only participants with-
out redness or skin erosion (Brunner 2012; Byers 1995). Three
trials included only participants with redness and/or skin ero-
sion (Baatenburg de Jong 2004; Buckley 2014; Wang 2011). The
two remaining trials did not report the proportion of participants
with skin problems in the perineal environment (Dieter 2006;
Schoonhoven 2015).
Interventions
Eight trials compared the application of a topical skin care product
versus another topical skin care product for the prevention and/or
treatment of incontinence-associated dermatitis (IAD) (first com-
parison, see Types of interventions). Because the main function of
the products (moisturising versus skin protecting) was not always
clear, we classified all topical skin care products broadly into skin
cleansers and leave-on products. Leave-on products include mois-
turisers, skin protectants/barriers, and other functions, whether
combined or not into one product.
• Two trials compared no-rinse skin cleansers with soap and
water for the prevention (and treatment) of IAD (Cooper 2001;
Byers 1995).
• Eight trials compared various leave-on products
(moisturisers, skin protectants/barriers, whether combined or
not into one product) as follows.
◦ One trial compared Sudocrem with a standard zinc
oxide cream for the prevention and treatment of IAD (Anthony
1987).
◦ A second trial compared a zinc oxide oil with a film-
forming skin product for the prevention and treatment of IAD
(Baatenburg de Jong 2004).
◦ A third trial compared a no-rinse skin cleanser and a
leave-on product with a washcloth with cleansing, moisturising
and skin protecting properties for the prevention and treatment
of IAD (Dieter 2006).
◦ A fourth trial compared a no-rinse skin cleanser and a
skin cream with soap and water combined with a lotion for the
prevention and treatment of IAD (Lewis-Byers 2002).
◦ A fifth trial compared a no-rinse skin cleanser and
moisturiser combined with a film-forming skin product with a
cleansing/moisturising/skin protecting washcloth for the
prevention of IAD (Brunner 2012).
◦ A sixth trial compared Desitin and Calmoseptine, two
commercial zinc oxide based products, for the treatment of IAD
(Buckley 2014).
◦ A seventh trial compared a zinc oxide cream with a
petrolatum ointment and a film-forming skin product for the
treatment of IAD (Kennedy 1996).
◦ An eighth trial compared Dermlin and Genetime for
the treatment of IAD (Wang 2011).
Two trials compared a structured skin care procedure with an
unstructured skin care procedure (second comparison, see Types
of interventions).
• One trial compared a washcloth with cleansing,
moisturising, and protecting properties with soap and water for
the prevention and treatment of IAD (Beeckman 2011).
• One trial compared a washcloth impregnated with a lotion
with soap and water for the prevention and treatment of any skin
abnormalities and significant skin lesions (Schoonhoven 2015).
Two trials compared different frequencies of application of topical
skin care products (fourth comparison, see Types of interventions).
• One trial compared two frequencies of a structured skin
care procedure, including a skin cleanser and a leave-on product,
13Interventions for preventing and treating incontinence-associated dermatitis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for the prevention and treatment of IAD: every six versus 12
hours (Conley 2014).
• One trial compared three frequencies of the application of a
film-forming skin product in the treatment of IAD: every 24 and
48 hours versus 72 hours for the treatment of IAD (Kennedy
1996).
Length of treatment
Most trials (n =9) had a treatment period of 15 days or less. In three
trials, nursing home residents were treated for three weeks (Lewis-
Byers 2002), six weeks (Schoonhoven 2015), or three months
(Beeckman 2011). In one trial the length of treatment was not
reported (Dieter 2006).
Sample size
Four trials had a sample size of 50 or less participants (Baatenburg
de Jong 2004; Byers 1995; Lewis-Byers 2002; Kennedy 1996). In
six trials, the sample size varied between 50 and 100 (Anthony
1987; Brunner 2012; Conley 2014; Cooper 2001; Dieter 2006;
Wang 2011). In three trials, more than 100 participants were in-
cluded (Beeckman 2011; Buckley 2014; Schoonhoven 2015). The
smallest sample size was 10 (Byers 1995), and the largest 450
(Schoonhoven 2015). Only the trial of Beeckman 2011, with a
sample size of 141 participants, mentioned that this sample size
was sufficient for a statistical power of 0.85 (α = 0.05).
Ongoing Studies
There are two ongoing studies (NCT02570139 2015;
NCT02690753 2016).
Excluded studies
In total, we excluded 24 trials from this review (see Characteristics
of excluded studies), for the following reasons.
• Six trials were not quasi-RCTs (Bliss 2007; Dealey 1995;
Holroyd 2014; Kyung 2014; Lyder 1992, Zehrer 2004).
• Twelve trials did not encompass any topical skin care
product (Al-Samarrai 2007; Bates-Jensen 2003; Bennett 1998;
Brown 1994; Denat 2011; Fader 2003; Leiby 1994;
Netta-Turner 2008; Pittman 2012; Shin 2012; Su 2015; Sugama
2012).
• One trial was not developed for the prevention or treatment
of IAD (Pinedo 2012).
• One trial was restricted to the trial protocol (Bauer 2007).
• Two trials included participants younger than 18 years (Iraji
2003; James 1975).
• One trial concerned the effectiveness of implementation
strategies not effectiveness of products/procedures (Harries 2016)
• One trial was finished prematurely, no reliable results were
possible (NCT02475512 2015).
Risk of bias in included studies
Allocation
The risk of bias associated with random sequence generation was
low in five trials (Baatenburg de Jong 2004; Beeckman 2011;
Buckley 2014; Cooper 2001; Schoonhoven 2015), high in three
trials (Conley 2014; Dieter 2006; Lewis-Byers 2002), and re-
mained unclear in five trials (Anthony 1987; Brunner 2012; Byers
1995; Kennedy 1996;Wang 2011). Baatenburg de Jong 2004 used
a computerised randomisation list provided by an independent
biostatistics centre. Schoonhoven 2015 used a computerised ran-
domisation list set up by an independent statistician. Beeckman
2011 and Buckley 2014 performed a computerised randomisa-
tion at their own research centre. Cooper 2001 used unmarked
envelopes to randomise patients (first research site) or wards (other
research sites). Conley 2014 assigned participants enrolled on even
numbered days to the intervention group and those enrolled on
odd numbered days to the control group. Dieter 2006 assigned
participants based on the last digit of their medical record number.
Lewis-Byers 2002 assigned participants in odd numbered rooms
to the trial protocol and participants in even numbered rooms
to the control group. The methods used by Conley 2014, Dieter
2006 and Lewis-Byers 2002 were associated with a high risk of
bias because allocation could be foreseen.
The risk of bias associated with allocation concealment was low in
one trial (Buckley 2014), high in three trials (Conley 2014; Dieter
2006; Lewis-Byers 2002), and remained unclear in the remaining
nine trials. In the study of Buckley 2014, an independent surgi-
cal research unit, not linked to the trialists, performed the treat-
ment allocation. Conley 2014 used odd and even numbered days
for treatment allocation. Dieter 2006 used the last digit of med-
ical record numbers for treatment allocation. Lewis-Byers 2002
used odd and even numbered rooms for treatment allocation. The
methods used byConley 2014,Dieter 2006 and Lewis-Byers 2002
were associated with a high risk of bias because allocation could
be foreseen.
Blinding
The risk of performance bias remained unclear in one trial
(Anthony 1987). Anthony 1987 mentioned a double-blind design
but the researchers provided no further details. Blinding of par-
ticipants and personnel was not possible in 12 trials due to visual
differences in appearance and use of the skin care products.
The risk of detection bias was low in two trials (Buckley 2014;
Cooper 2001), unclear in three trials (Anthony 1987;Dieter 2006;
Wang 2011), and high in the remaining eight trials. Cooper 2001
and Buckley 2014 blinded the outcome assessment by asking ex-
perts to assess the outcomes using photographs. The Buckley 2014
trial also mentioned the removal of residual ointment using min-
eral oil to avoid traces of product being visible on the photographs.
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Anthony 1987 mentioned a double-blind design but provided no
further details. In the remaining trials no information on the as-
sessment procedure was given, or the assessment was not blinded.
Incomplete outcome data
The risk of attrition bias due to incomplete outcome data was
low in six trials (Baatenburg de Jong 2004; Buckley 2014; Byers
1995; Conley 2014; Cooper 2001; Lewis-Byers 2002), high in
two trials (Anthony 1987; Brunner 2012), and unclear in the
remaining five trials (Beeckman 2011; Dieter 2006; Kennedy
1996; Schoonhoven 2015; Wang 2011).
Selective reporting
The risk of reporting bias due to selective reporting was low in
eight trials (Baatenburg de Jong 2004; Beeckman 2011; Buckley
2014; Byers 1995; Conley 2014; Cooper 2001; Lewis-Byers 2002;
Schoonhoven 2015), high in four trials (Anthony 1987; Brunner
2012; Dieter 2006; Kennedy 1996), and unclear in one trial (
Wang 2011). Anthony 1987 did not report the results in sufficient
detail (e.g. no parameters of erythema readings, only proportions
of participants with change in red band). Brunner 2012 did not
report the statistical methods clearly and provided only P values
for some results. Furthermore, Brunner 2012 did not give any
reason for using a restricted sample size to study the time for skin
breakdown. Dieter 2006 and Kennedy 1996 did not report the
statistical methods and provided no P values.
Other potential sources of bias
One trial used a cross-over design without a washout period be-
tween interventions (Byers 1995). Consequently, bias could have
been introduced from a carry-over effect.
At least five trials were sponsored by industry (Baatenburg de Jong
2004; Buckley 2014; Byers 1995; Cooper 2001; Kennedy 1996).
Concerning the trial of Baatenburg de Jong 2004, the industrial
company did the randomisation and data analysis. Concerning
the trial of Kennedy 1996, one of the authors was a member of the
company delivering one of the trial products. In another trial the
corresponding author was a member of the company delivering
the trial products (Lewis-Byers 2002). It was not clear how the
involvement of industry may have influenced the results.
Detailed results of the risk of bias are presented in Characteristics
of included studies and in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Any
topical skin care product versus another topical skin care product;
Summary of findings 2 Any skin care procedure (method
or frequency of application) versus any unstructured skin care
procedure; Summary of findings 3 Any method of application of
a topical skin care product versus another method of application
of the topical skin care product; Summary of findings 4 Any
frequency of application of a topical skin care product versus
another frequency of application of the topical skin care product
In this section, we described separately the data of included tri-
als because of variation in tested skin care products or procedures
and reported outcomes. The tables in Characteristics of included
studies present a more detailed description of the trials. If pos-
sible, we entered the data in Review Manager 5 to calculate risk
ratios (RRs) and confidence intervals (CIs) for use in this sec-
tion (RevMan 2014). The tables in Data and analyses present an
overview of all relevant outcomes measured in the included studies
and the numbers of studies measuring each outcome. We did not
present effect sizes (totals and subtotals), as we did not perform
any meta-analyses.
1. Any topical skin care product versus another
topical skin care product
For the same reason as described in Included studies, the topi-
cal skin care products are divided into skin cleansers and leave-
on products. Leave-on products consist of moisturisers, skin pro-
tectants/barriers, and other functions, whether combined or not,
into one product.
Skin cleansers
Two trials compared a skin cleanser with soap and water (Byers
1995; Cooper 2001).
The Cooper 2001 trial compared the use of the skin cleanser Clin-
isan with the standard use of soap and water for the prevention and
treatment of incontinence-associated dermatitis (IAD). Clinisan
consists of a surfactant, emollients, dimethicone, an antibacterial
agent, and perfume, and has a pH of 5.5.
The Byers 1995 trial compared the use of the skin cleanser Triple
Care Cleanser with the standard use of soap and water for the
prevention of IAD in a cross-over trial.
Primary Outcomes
Number of participants with incontinence-associated
dermatitis (IAD) (residual, i.e. not healed)
Not reported.
Number of participants with IAD (new) (only suitable to
evaluate interventions for preventing IAD)
TheCooper 2001 trial (n = 87) demonstrated that less participants
treated with Clinisan developed IAD during 14 days of follow-up.
In the intervention group 6/33 (18.2%) of the elderly developed
IAD during the study, and in the control group 15/32 (46.9%) of
the elderly developed IAD during the study. According to Analysis
1.2, this effect was significant in favour of Clinisan (RR 0.39, 95%
CI 0.17 to 0.87; low quality evidence; Summary of findings for
the main comparison).
Number of participants not satisfied with treatment
Not reported.
Secondary Outcomes
Participants’ observations
Not reported.
Quantification of symptoms (objective measures)
Not reported.
Clinicians’ observations
Not reported.
Quality of life
Not reported.
Economic data
The Byers 1995 trial (n = 10) demonstrated that for an episode
of urinary incontinence, the mean difference (MD) in cleansing
time was 3.87 minutes in favour of the Triple Care Cleanser (95%
CI -4.31 to -3.43; P < 0.001; Analysis 1.4). For an episode of
both urinary and faecal incontinence, the MD in cleansing time
was 9.68 minutes in favour of the Triple Care Cleanser (95% CI -
11.71 to -7.65; P < 0.001; Analysis 1.4). The results of this cross-
over trial were based onmeasurements over five treatment periods.
The researchers did not provide results for the separate treatment
periods. We did not find recent contact details to request more
detailed information.
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Adverse effects (of the interventions)
Not reported.
Other outcomes (non-prespecified outcomes judged
important when performing the review)
These outcomes were: IAD severity; number of participants with
IAD completely healed, and number of participants with bacterial
or fungal infection.
Not reported.
Leave-on products (moisturisers, skin protectants/barriers,
combined or not)
Eight trials compared various leave-on products (moisturisers, skin
protectants/barriers, whether combined or not into one product)
(Anthony 1987; Baatenburg de Jong 2004; Brunner 2012; Buckley
2014; Dieter 2006; Lewis-Byers 2002; Kennedy 1996; Wang
2011).
The Anthony 1987 trial compared two different zinc oxide creams,
Sudocrem and a standard zinc oxide cream. Sudocrem is claimed
to have antiseptic properties and consists of 15.25% zinc oxide,
4.0% hydrous wool fat (hypoallergenic), 1.01% benzyl benzoate,
0.15%benzyl cinnamate, and 0.39%benzyl alcohol. The standard
zinc oxide cream consists of 32.0% zinc oxide, 32.0% arachis oil,
0.045% calcium hydroxide, 0.5% oleic acid, and 8% wool fat.
Both creams were applied liberally to groin and buttocks with each
diaper/pad change for 14 days.
The Baatenburg de Jong 2004 trial compared a zinc oxide oil
with the film-forming skin product Cavilon No Sting Barrier Film
for the prevention and treatment of IAD. The zinc oxide oil was
applied in accordance with nursing home protocol and removed
every morning and evening before re-application, and if necessary
during diaper/pad changes. The film-forming skin product was
applied every 24, 48, or 72 hours, depending on skin condition
and frequency of diaper/pad change.
The Brunner 2012 trial compared the use of a cleansing and mois-
turising product followed by the application of a film-forming skin
product with the use of a washcloth (with cleansing, moisturising,
and protecting properties) for the prevention of IAD. The trial
products were Cavilon Skin Cleanser, Cavilon No Sting Barrier
Film, and Comfort Shield Perineal Care Washcloth Dimethicone
3%.
The Buckley 2014 trial compared Desitin and Calmoseptine, two
zinc oxide based products, for the treatment of IAD. Desitin is
a paste consisting of 40% zinc oxide, lanolin, petrolatum, and
cod liver oil. Calmoseptine is an ointment consisting of 20% zinc
oxide, menthol, chlorothymol, glycerine, lanolin, sodium bicar-
bonate, phenol, and thymol. In each group, one of the zinc ox-
ide products was applied twice daily and after each incontinence
episode for six days. In addition, in both groups a structured skin
care procedure for the treatment of IAD was applied. The skin
care procedure was provided twice daily and as required by in-
continence episodes. As part of the skin care procedure, nurses
removed wet or soiled diapers/pads, cleansed the skin gently with
a polyhexanide wound cleansing solution using gauze pads and
soft tissue and applied a thin layer of zinc oxide product prior to
putting a new diaper/pad on.
The Dieter 2006 trial compared the combined use of a no-rinse
skin cleanser and a leave-on product with the use of a washcloth
with cleansing, moisturising, and skin protecting properties for
the prevention and treatment of IAD. The researchers did not give
the commercial name nor the ingredients of the products studied.
This study was described as an abstract. The outcomes reported
were not suitable for this review. The authors did not respond to
our request for more information.
The Lewis-Byers 2002 trial compared the combined use of a no-
rinse skin cleanser plus a skin cream with the use of soap and water
plus a lotion for the prevention and treatment of IAD. The no-
rinse skin cleanser tested was Cavilon Antiseptic Skin Cleanser.
The skin cream was Cavilon Durable Barrier Cream. The study
authors did not provide the commercial name nor the ingredients
of the lotion.
The participants of the first group were cleansed with the Cav-
ilon Antiseptic Skin Cleanser after each incontinent episode, and
during the first incontinent episode per shift, a skin cream was
applied. The participants of the second group were cleansed with
soap (liquid or bar) and a disposable washcloth and water followed
by the application of a lotion after each incontinence episode. Staff
time per participant per day was measured for gathering supplies,
setting supplies, cleansing participants, and application of lotion
or skin cream.
TheKennedy 1996 trial compared a zinc oxide cream (Baza) with a
petrolatum ointment (Peri-Care) and a film-forming skin product
(Cavilon No Sting Barrier Film) for the treatment of IAD. The
first group received Baza three times per day, and as necessary
during 12 days. The second group received Peri-Care three times a
day, and as necessary. The third group received Cavilon No Sting
Barrier Film with a swab applicator every 24, 48, or 72 hours.
The Wang 2011 study compared two commercial leave-on prod-
ucts, Dermlin and Genetime, for the treatment of IAD in the peri-
anal environment. Dermlin was described as an advanced wound
healing product. Genetimewas described as a recombinant human
epidermal growth factor.
This study was described as a short report in Chinese. Neither
the intervention nor the outcomes were clear from the English
translation; we found no contact details of the study author to ask
for more information.
Primary Outcomes
Number of participants with incontinence-associated
dermatitis (IAD) (residual, i.e. not healed)
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In the Lewis-Byers 2002 trial (n = 31), 2/18 (11.1%) of the partici-
pants cared for with Cavilon Antiseptic Skin Cleanser andCavilon
Durable Barrier Cream had IAD at the end of the trial period. Of
the participants cared for with soap and water plus the lotion, 4/
13 (30.8%) had IAD at the end of the trial period. According to
analysis in Review Manager 5 (RevMan 2014), this difference, in
favour of Cavilon Antiseptic Skin Cleanser combined with Cav-
ilon Durable Barrier Cream, was not significant (RR 0.36, 95%
CI 0.08 to 1.68; very low quality evidence; Summary of findings
for the main comparison; Analysis 1.1).
Intention-to-treat analysis of the results from the Buckley 2014
trial (n=142) demonstrated that IAD did not heal in 66/73
(90.4%) participants from the Desitin group and 54/69 (78,3%)
participants from the Calmoseptine group. According to analysis
in Review Manager 5 (RevMan 2014), this difference, in favour
of Calmoseptine, was not significant (RR 1.16, 95% CI 1.00 to
1.34; moderate quality evidence; Summary of findings for the
main comparison; Analysis 1.1).
Number of participants with IAD (new) (only suitable to
evaluate interventions for preventing IAD)
During the Anthony 1987 trial (n = 57), 2/11 (18.2%) partici-
pants from the standard zinc oxide group and 3/16 (18.8%) par-
ticipants from the Sudocrem group, who had no IAD at start of
the study, developed IAD (RR 1.03, 95% CI 0.20 to 5.19; low
quality evidence; Summary of findings for the main comparison;
Analysis 1.2).
The Brunner 2012 trial (n = 64) demonstrated that the number
of participants who developed IAD did not differ significantly be-
tween the group cared for with Cavilon SkinCleanser and Cavilon
No Sting Barrier Film and the group washed with the Comfort
Shield Perineal Care Washcloth Dimethicone 3% (RR 0.83, 95%
CI 0.35 to 1.95; low quality evidence; Summary of findings for
the main comparison; Analysis 1.2). In the group cared for with
Cavilon Skin Cleanser and Cavilon No Sting Barrier Film, 7/31
participants (22.6%) developed IAD. In the group washed with
the Comfort Shield Perineal Care Washcloth Dimethicone 3%, 9/
33 (27.3%) participants developed IAD.
Number of participants not satisfied with treatment
Not reported.
Secondary Outcomes
Participants’ observations
Not reported.
Quantification of symptoms (objective measures)
One trial, the Buckley 2014 trial (n = 121), measured the change
in surface affected by IAD in patients treated with Desitin (n =
65) and patients treated with Calmoseptine (n = 56). The change
in surface area affected by IAD was significantly more reduced
with the use of Calmoseptine (P = 0.001, MD 81.60 cm², 95%
CI 36.87 to 127.33, Analysis 1.3).
Clinicians’ observations
Not reported.
Quality of life
Not reported.
Economic data
Three trials reported on the cost of products (Baatenburg de Jong
2004; Brunner 2012; Kennedy 1996).
The Baatenburg de Jong 2004 trial (n = 39) suggested that the cost
of trial products and application-related products (price year not
reported) was on average highest for zinc oxide oil (EUR 14.16,
standard deviation (SD) 1.83) versus Cavilon No Sting Barrier
Film (EUR 7.55, SD 8.60). Nursing time spent was also on aver-
age higher for zinc oxide oil (208.95 minutes, SD 53.84) versus
Cavilon No Sting Barrier Film (161.96 minutes, SD 55.55). As a
consequence, the total costs were on average higher for zinc oxide
oil (EUR 102.96, SD 23.25) versus Cavilon No Sting Barrier Film
(EUR 76.13, SD 25.48). The difference between groups was not
measured statistically and so we cannot be sure if differences in
average costs are real or not. We could not analyse these economic
data in Review Manager 5 (RevMan 2014), because the number
of participants per group was not reported, and the study authors
did not respond to our request for more details.
The Brunner 2012 trial (n = 64) reported that the product costs
per trial day (price year not reported) were significantly higher
for the combined use of Cavilon Skin Cleanser and Cavilon No
Sting Barrier Film (USD 6.59, n = 31) compared to the use of
Comfort Shield Perineal Care Washcloth Dimethicone 3% (USD
2.67, n = 33) (P = 0.006). Because no SDs or other statistics were
reported, we were unable to undertake analysis in ReviewManager
5 (RevMan 2014).
The Kennedy 1996 trial (n = 40) suggested that Peri-Care (n = 8)
was on average less expensive than Baza (n = 8) in terms of daily
cost of product use (Peri-Care USD 0.8 versus Baza USD 1.2)
(price year 1995). Baza was less expensive than Cavilon No Sting
Barrier Film if Cavilon No Sting Barrier Film was applied every
24 (n = 8) or 48 hours (n = 8) (Baza USD 1.2 versus Cavilon No
Sting Barrier Film USD 2.3 or USD 1.1). Baza was on average
more expensive than Cavilon No Sting Barrier Film, if the latter
was applied every 72 hours (n = 8) (Baza USD 1.2 versus Cavilon
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No Sting Barrier Film USD 0.8). Peri-Care was on average less
expensive than Cavilon No Sting Barrier Film if the latter was
applied every 24 or 48 hours (Peri-Care USD 0.8 versus Cavilon
No Sting Barrier Film USD 2.3 or USD 1.1). Peri-Care costs on
average the same as Cavilon No Sting Barrier Film if the latter was
applied every 72 hours (USD 0.8). No levels of significance were
provided and as a consequence it is unclear whether any difference
in average costs are real. Due to the limited reporting of statistical
data, we were unable to perform analysis in Review Manager 5
(RevMan 2014). We found no recent contact details of the study
authors to ask for more information.
One trial, the Lewis-Byers 2002 trial (n = 31), reported on staff
time. Staff time was on average shorter for the combined use of
Cavilon Antiseptic Skin Cleanser plus Cavilon Durable Barrier
Cream than for the combineduse of soap andwater plus the lotion.
In the first group (n = 18), staff time was 41 minutes per day
for an average of seven incontinence episodes per day. The mean
duration of cleansing was five minutes, and for the application of
CavilonDurable Barrier Cream, twominutes. In the second group
(n = 13), staff time was 120 minutes per day for an average of eight
incontinence episodes per day. The mean duration of cleansing
was 13minutes, and for the application of the lotion, twominutes.
No levels of significance were provided and as a consequence it is
unclear whether any difference in average staff time are real. It was
not possible to undertake analysis in Review Manager 5 because
SDs were not reported (RevMan 2014). The study authors did
not respond on our request for more details.
One trial, the Baatenburg de Jong 2004 trial (n = 39), reported
on incremental cost-effectiveness, reported as the incremental cost
per 1 point improvement in skin condition. The incremental cost
per 1 point improvement was EUR 98.06 for zinc oxide oil, and
EUR 28.36 for Cavilon No Sting Barrier Film (price year not
reported). No estimate of the imprecision around this estimate of
incremental cost-effectiveness was reported. Following guidance
from Campbell and Cochrane Economics Methods Group, it is
not appropriate to consider meta-analysis of such data. Rather
consideration should focus on what issues might determine such
results.
Adverse effects (of the interventions)
The Buckley 2014 trial reported that no adverse effects occurred
during the study while using Desitin and Calmoseptine.
Other outcomes (non-prespecified outcomes judged
important when performing the review)
These outcomes were: IAD severity; number of participants with
IAD completely healed, and number of participants with bacterial
or fungal infection.
IAD severity
Four trials reported on IAD severity (Anthony 1987; Baatenburg
de Jong 2004; Kennedy 1996; Lewis-Byers 2002).
The Anthony 1987 trial (n = 57) demonstrated a reduction in IAD
severity in 92.3% of the participants from the Sudocrem group (n
= 29) and 37.5% of the participants from the standard zinc oxide
group (n = 28) after seven days. A reduction in IAD severity was
identified in 84.6% of the participants from the Sudocrem group
and 50.0% of the participants from the standard zinc oxide group
after 14 days. The researchers mentioned a significantly greater
improvement of IAD severity in favour of Sudocrem at both time
points (P < 0.01). Because only percentages were provided, it was
not possible to undertake an analysis in Review Manager 5for
the outcome ’IAD severity’ (RevMan 2014). We found no recent
contact details of the study authors to ask for more information.
The Baatenburg de Jong 2004 trial (n = 39) demonstrated an
improvement in IAD severity in participants treated with zinc
oxide oil as in participants treated with Cavilon No Sting Barrier
Film, with a significantly greater improvement in the group treated
with Cavilon No Sting Barrier Film (P = 0.04). Because only a P
value was reported, it was not possible to undertake an analysis in
Review Manager 5 (RevMan 2014).
The Kennedy 1996 trial (n = 40) demonstrated that the IAD
severity improved significantly in participants treated with Peri-
Care (n = 8), Baza (n = 8) or Cavilon No Sting Barrier Film (n
= 24). No statistics were provided. None of the groups showed a
significantly greater improvement in IAD severity than the other.
Due to the limited reporting of statistical data, we were unable
to perform analysis in Review Manager 5 (RevMan 2014). We
found no recent contact details of the study authors to ask for
more information.
The Lewis-Byers 2002 trial (n = 31) demonstrated that the severity
of IADdidnot significantly differ between the group cared forwith
Cavilon Antiseptic Skin Cleanser and Cavilon Durable Barrier
Cream (mean score 0.28/4, SD 0.83, n = 18) and the group cared
for with soap and water plus the lotion (mean score 0.77/4, SD
1.30, n = 13). TheMDwas -0.49 (95% CI -1.29 to 0.31; Analysis
1.6).
Number of participants with IAD completely healed
One trial, theBuckley2014 trial (n =142), reported on the number
of participants with IAD completely healed during a follow-up
period of six days. Based on the intention-to-treat analysis, 15/
69 (21.7%) participants from the Calmoseptine group and 7/73
(9.6%) participants from the Desitin group completely healed
during the study. According to analysis in Review Manager 5 (
RevMan 2014), the difference, in favour of Calmoseptine, was not
significant (RR 0.44, 95% CI 0.19 to 1.02; Analysis 1.5).
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Number of participants with bacterial or fungal infection
One trial, the Buckley 2014 trial (n = 142), reported on the num-
ber of participants with fungal infections as a secondary outcome.
During this trial, 4/142 (2.8%) participants were withdrawn be-
cause of fungal infections in the IAD area.
2. Any skin care procedure (method or frequency of
application) versus any unstructured skin care
procedure
Two trials compared a skin care procedure (method or frequency of
application) versus soap andwater (Beeckman 2011; Schoonhoven
2015).
The Beeckman 2011 trial compared a structured skin care pro-
cedure using a washcloth with cleansing, moisturising, and skin
protecting properties with the standard use of soap and water. The
trial washcloth was the Comfort Shield Perineal Care Washcloth
Dimethicone 3%.
The intervention group was washed daily with theComfort Shield
Perineal Care Washcloth at routine perineal skin hygiene times,
and after each diaper/pad change. No towel rubbing was allowed.
In case of an extremely soiled skin, a soft washcloth and lukewarm
water to remove soiling and a soft towel were used to dry the skin.
The control group was washed with a soft washcloth, soap (pH
6.5 to 7.5) and water at routine perineal skin hygiene times, and
after each diaper/pad change.
The Schoonhoven 2015 trial compared the use of a washcloth
impregnated with a lotion with soap and water for the prevention
and treatment of skin abnormalities and skin lesions. The trial
washcloths were the Wet Wash Gloves from Abena.
The intervention group was washed daily in bed with the Wet
Wash Gloves which were heated in the microwave before use. No
towel rubbing was allowed. The control group was washed daily
using tap water and soap (different types), wash gloves, and towels.
The report of this trial provides results on skin abnormalities (e.g.
erythema, erosions, discolorations of the wound bed) and signif-
icant skin lesions (non-intact skin). These results, however, were
not specific for IAD, but included any kind of skin abnormalities
and lesions over the whole body.
Primary Outcomes
Number of participants with incontinence-associated
dermatitis (IAD) (residual, i.e. not healed)
The Beeckman 2011 trial (n = 141) demonstrated that, after 120
days, significantly fewer participants washed with the Comfort
Shield Perineal CareWashcloth (n = 73) had IAD versus the group
washed with soap and water (n = 68). After adjusting for clustering
effect, 7.9% participants washed with the washcloth had IAD
versus 25.9% of the participants washed with soap and water (RR
0.31, 95% CI 0.12 to 0.79; moderate quality evidence; Summary
of findings 2; Analysis 2.1).
Number of participants with IAD (new) (only suitable to
evaluate interventions for preventing IAD)
Not reported.
Number of participants not satisfied with treatment
Not reported.
Secondary Outcomes
Participants’ observations
Not reported.
Quantification of symptoms (objective measures)
Not reported.
Clinicians’ observations
Not reported.
Quality of life
Not reported.
Economic data
Not reported.
Adverse effects (of the interventions)
The Schoonhoven2015 trial reported the absence of any Suspected
Unexpected Serious Adverse Reaction occurring while comparing
the use of a washcloth impregnated with a lotion with soap and
water.
Other outcomes (non-prespecified outcomes judged
important when performing the review)
These outcomes were: IAD severity; number of participants with
IAD completely healed, and number of participants with bacterial
or fungal infection.
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IAD severity
One trial, the Beeckman 2011 trial (n = 141), reported on IAD
severity. At the end of this trial, the IAD severity was significantly
less in the group washed with the Comfort Shield Perineal Care
Washcloth (n = 73) versus the group washed with soap and water
(n = 68) (MD -2.50, 95% CI -3.19 to -1.81, Analysis 2.2).
Number of participants with IAD completely healed
Not reported.
Number of participants with bacterial or fungal infection
The Beeckman 2011 trial also reported on the number of partic-
ipants developing any bacterial or fungal infection. During this
trial, no participants developed any bacterial or fungal infection.
3. Any method of application of a topical skin care
product versus another method of application of the
topical skin care product
No suitable trials were found.
4. Any frequency of application of a topical skin care
product versus another frequency of application of
the topical skin care product
Two trials compared different frequencies of application of topical
skin care products (Conley 2014; Kennedy 1996)
The Conley 2014 trial tested a structured skin care procedure,
including the application of a skin cleanser and a leave-on product,
for the prevention and treatment of IAD. The skin cleanser and
the leave-on product were applied every six hours or every 12
hours. The skin care procedure consisted of gentle cleansing of
the skin with the skin cleanser containing Aloe vera mixed with
water and a cleansing lotion followed by patting the skin dry. If
no erythema was observed, a leave-on product with silicone was
applied. If erythema was present, a leave-on product with zinc
oxide and menthol was applied.
The Kennedy 1996 trial compared three frequencies of the appli-
cation of a film-forming skin product (Cavilon No Sting Barrier
Film: every 24, 48, or 72 hours.
Primary Outcomes
Number of participants with incontinence-associated
dermatitis (IAD) (residual, i.e. not healed)
The Conley 2014 trial (n = 99) identified no significant difference
in the number of participants with IAD when performing the
skin care procedure every six hours (56.4%) versus every 12 hours
(60.0%) (P = 0.718). We were unable to perform any analysis
in Review Manager 5 because the study authors only provided
percentages for the outcome of interest and no statistics onmissing
data (RevMan 2014). The study authors did not reply to our
request for more details.
Number of participants with IAD (new) (only suitable to
evaluate interventions for preventing IAD)
Not reported.
Number of participants not satisfied with treatment
Not reported.
Secondary Outcomes
Participants’ observations
Not reported.
Quantification of symptoms (objective measures)
Not reported.
Clinicians’ observations
Not reported.
Quality of life
Not reported
Economic data
One trial, the Kennedy 1996 trial (n = 40), reported on the cost
of products (Price year 1995). This trial demonstrated that the
application of Cavilon No Sting Barrier Film every 72 hours (n =
8) was the least expensive (USD 0.8), followed by the application
every 48 hours (n = 8) (USD 1.1) and the application every 24
hours (n = 8) (USD 2.3). Because no SDs were reported, we were
unable to undertake an analysis in Review Manager 5 (RevMan
2014).
Adverse effects (of the interventions)
Not reported.
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Other outcomes (non-prespecified outcomes judged
important when performing the review)
These outcomes were: IAD severity; number of participants with
IAD completely healed, and number of participants with bacterial
or fungal infection.
IAD severity
One trial, the Kennedy 1996 trial (n = 40), reported on the IAD
severity. This trial demonstrated that the IAD severity improved
significantly in participants treated with Cavilon No Sting Barrier
Film every 24 hours (n = 8), every 48 hours (n = 8) or every 72
hours (n = 8). No statistics were mentioned. None of the groups
showed a significantly greater improvement in IAD severity than
the other. Due to the limited reporting of statistical data, we were
unable to perform any analysis in Review Manager 5 (RevMan
2014). We found no recent contact details of the study authors to
ask for more information.
Number of participants with IAD completely healed
Not reported.
Number of participants with bacterial or fungal infection
Not reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure
Patient or population: adults with incont inence
Setting: nursing homes
Intervention: any skin care procedure (method or f requency of applicat ion)
Comparison: any unstructured skin care procedure
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with any unstruc-
tured skin care proce-
dure (B)
Risk with any skin care
procedure (method or
frequency of applica-
tion) (A)
Number of participants
with IAD (residual, i.e.
not healed)
(1) Washcloth with
cleansing, moisturis-
ing, and protect ing
propert ies (A) versus
water and pH neutral
soap (B)
Study populat ion RR 0.31
(0.12 to 0.79)
121
(1 RCT)
⊕⊕⊕©
MODERATE
Based on one study.
259 per 1.000 80 per 1.000
(31 to 204)
Number of participants
with IAD (new)
No data for this out-
come were reported in
the eligible studies
Number of participants
not satisfied with treat-
ment
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to IAD
No data for this out-
come were reported in
the eligible studies24
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Number of participants
with pain due to skin
care product or proce-
dure
No data for this out-
come were reported in
the eligible studies
Adverse reaction due
to the skin care product
or procedure, e.g. skin
irritation, rash, itching,
allergic
reaction
No data for this out-
come were reported in
the eligible studies
Incremental cost-ef-
fectiveness
No data for this out-
come were reported in
the eligible studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IAD: incont inence-associated dermatit is; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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Any method of application of a topical skin care product versus another
method of application of the topical skin care product
Patient or population: adults with incont inence
Setting:
Intervention: any method of applicat ion of a topical skin care product
Comparison: any other method of applicat ion of the topical skin care product
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with any unstruc-
tured skin care proce-
dure (B)
Risk with any skin care
procedure (method or
frequency of applica-
tion) (A)
Number of participants
with IAD (residual, i.e.
not healed)
No data for this out-
come were reported in
the eligible studies
Number of participants
with IAD (new)
No data for this out-
come were reported in
the eligible studies
Number of participants
not satisfied with treat-
ment
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to IAD
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to skin
care product or proce-
dure
No data for this out-
come were reported in
the eligible studies
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Adverse reaction due
to the skin care product
or procedure, e.g. skin
irritation, rash, itching,
allergic
reaction
No data for this out-
come were reported in
the eligible studies
Incremental cost-ef-
fectiveness
No data for this out-
come were reported in
the eligible studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IAD: incont inence-associated dermatit is; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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Any frequency of application of a topical skin care product versus another
frequency of application of the topical skin care product
Patient or population: adults with incont inence
Setting:
Intervention: any f requency of applicat ion of a topical skin care product
Comparison: any other f requency of applicat ion of the topical skin care product
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with any unstruc-
tured skin care proce-
dure (B)
Risk with any skin care
procedure (method or
frequency of applica-
tion) (A)
Number of participants
with IAD (residual, i.e.
not healed)
No data for this out-
come were reported in
the eligible studies
Number of participants
with IAD (new)
No data for this out-
come were reported in
the eligible studies
Number of participants
not satisfied with treat-
ment
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to IAD
No data for this out-
come were reported in
the eligible studies
Number of participants
with pain due to skin
care product or proce-
dure
No data for this out-
come were reported in
the eligible studies
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Adverse reaction due
to the skin care product
or procedure, e.g. skin
irritation, rash, itching,
allergic
reaction
No data for this out-
come were reported in
the eligible studies
Incremental cost-ef-
fectiveness
No data for this out-
come were reported in
the eligible studies
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; IAD: incont inence-associated dermatit is; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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D I S C U S S I O N
The aim of this review was to assess and compare the effectiveness
of various products and procedures to prevent and treat inconti-
nence-associated dermatitis (IAD) in adults. In this context, the
review focused on topical skin care products, structured skin care
procedures, application methods for topical skin care products,
and frequency of application of topical skin care products.
Summary of main results
Primary outcomes
Four trials assessed the effectiveness of topical skin care prod-
ucts (skin cleansers and leave-on products) against the outcome
’number of participants with IAD (residual/new)’ (Brunner 2012;
Buckley 2014; Cooper 2001; Lewis-Byers 2002). Two of these tri-
als (Brunner 2012; Lewis-Byers 2002) tested a combined use of
skin care products in each trial group (for example, a skin cleanser
and a leave-on product). One trial compared the use of a skin
cleanser with soap andwater (Cooper 2001). Another trial assessed
whether a structured skin care procedure could reduce the same
outcome (as above) in comparisonwith soap andwater (Beeckman
2011).
Based on the included trials, we found low quality evidence for
the effectiveness of a skin cleanser (Clinisan) compared with soap
and water. We found evidence of moderate quality for the effec-
tiveness of a structured skin care procedure (using a washcloth
with cleansing, moisturising, and protecting properties; Comfort
Shield Perineal Care Washcloth Dimethicone 3%) compared with
soap and water. No differences were found between topical skin
care products (skin cleansers and leave-on products) in reducing
the number of participants with IAD. However, it should be no-
ticed that the sample size of the latter trials was rather small (< 100
participants), except for the Buckley 2014 trial (n = 142) .
Secondary outcomes
One trial assessed the outcomes ’size of the skin lesion’ (surface
affected by IAD) and ’number of participants completely healed’
(Buckley 2014). The researchers compared two different zinc ox-
ide based leave-on products (Desitin and Calmoseptine) and iden-
tified a significant difference in favour of Calmoseptine for both
outcomes. However, the two products differed in the amount of
zinc oxide being applied (20% in Calmoseptine, 40% in Desitin)
and the presence of other active ingredients (such as menthol in
Calmoseptine and lanolin, petrolatum, and cod liver oil in De-
sitin). Consequently, it is not clear which amount of zinc oxide is
optimal or which ingredients are pivotal for the treatment of IAD.
Low quality evidence was found for economic data (’cost of prod-
uct’, ’staff time’, ’incremental cost-effectiveness’), based on a few
small studies.
Two trials compared the costs for daily use of various leave-on
products (zinc oxide based products, petrolatum ointment) with
those of a film-forming skin product (also a leave-on product)
(Baatenburg de Jong 2004; Kennedy 1996). Themethods used for
economic analysis varied across these trials. It should also be men-
tioned that the zinc oxide products and the petrolatum ointment
were applied more frequently than the film-forming skin product
(at least twice daily versus every 24, 48, or 72 hours). The find-
ings from the Kennedy 1996 study, which seem to be outdated,
indicated that the film-forming skin product Cavilon No Sting
Barrier Film was more expensive on average if applied on a daily
base. However, if this film-forming skin product could be applied
every 72 hours, then it would be less expensive on average than
the zinc oxide cream, Baza and the petrolatum ointment, Peri-
Care (Kennedy 1996). Furthermore, if the costs for application-
related products (gloves, spatula, gauze) were included, then the
film-forming skin product mentioned above, applied according to
participants’ needs, would be less expensive on average than the
zinc oxide oil (Baatenburg de Jong 2004). The lack of statistical
comparison hover means that no conclusion can be drawn about
differences in cost.
One trial reported that the cost for the daily use of a washcloth
with cleansing, moisturising and protecting properties (Comfort
Shield Perineal Care Washcloth Dimethicone 3%) was signifi-
cantly lower than the use of two separate leave-on products (Cav-
ilon Skin Cleanser and Cavilon No Sting Barrier Film) (Brunner
2012).
Staff time was assessed in two small trials comparing soap and wa-
ter with a skin cleanser (Byers 1995; Lewis-Byers 2002). The find-
ings from both trials indicated that staff time can be reduced when
using a no-rinse skin cleanser (including Triple Care Cleanser and
CavilonAntiseptic SkinCleanser). This could be expected aswash-
ing with a no-rinse skin cleanser does not need the filling and
emptying of a water basin and the drying of the participant with
a towel. However, no statistical comparisons were reported and
conclusions remain tentative.
The incremental cost-effectiveness was calculated for the com-
parison of zinc oxide oil with a film-forming skin protectant
(Baatenburg de Jong 2004). When using the film-forming skin
protectant Cavilon No Sting Barrier Film, the application fre-
quency, application-related product costs and staff time were on
average lower than when using zinc oxide oil. In addition, IAD
severity was also significantly lower.No estimate of the imprecision
around this estimate was provided and no guidance was provided
as to how interpret the incremental cost-effectiveness result. The
trial team however concluded that the total costs (for products and
staff time) per point improvement in IAD severity were in favour
of the film-forming skin protectant Cavilon No Sting Barrier Film
compared with zinc oxide oil.
Three trials reported results on the outcome ’IAD severity’ when
comparing various leave-on products (zinc oxide products, petro-
latum ointment, film-forming skin protectant). In one small trial
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(n = 34), IAD severity improved more when using the film-
forming skin protectant Cavilon No Sting Barrier Film compared
with zinc oxide oil (Baatenburg de Jong 2004). However, an-
other similar trial, found no significant difference comparing the
same film-forming skin protectant with the zinc oxide cream, Baza
(Kennedy 1996). The latter trial included only 16 participants.
A last trial found more improvement in terms of reduced skin
redness when using Sudocrem compared to a standard zinc oxide
cream (Anthony 1987). Because of other differences in compo-
sition of these two products (such as amount of zinc oxide ap-
plied), it was not clear whether the ingredients responsible for the
antiseptic properties of Sudocrem determined the outcome. As
described above, the trials of Anthony 1987, Baatenburg de Jong
2004 and Kennedy 1996 compared different leave-on products
with each other. The overall findings of these trials suggested that
IAD severity improved for all leave-on products.
One trial analysed the improvement in IAD severity when com-
paring a structured skin care procedure (washcloth with cleans-
ing, moisturising, and protecting properties) with soap and water
(Beeckman 2011). In this trial, only residents washed with the
washcloth (Comfort Shield Perineal CareWashclothDimethicone
3%) showed a significant improvement in IAD severity.
Overall completeness and applicability of
evidence
This review included 13 (quasi-)RCTs in a qualitative synthesis.
The trials provided data for only two of the three proposed pri-
mary outcomes (‘number of participants with IAD residual (i.e.
not healed)’ and ‘number of participants with IAD (new)’) and
three of the seven proposed secondary outcomes (‘quantification
of symptoms’, ‘economic data’ and ‘other outcomes’). We did not
find data on four of seven participant-important outcomes: ‘num-
ber of participants not satisfied with treatment’, ‘number of par-
ticipants with pain due to IAD’, ‘number of participants with pain
due to skin care products or procedure’ and ‘adverse reaction due
to skin care product or procedure’.
Although we included only 13 trials, this review contains results
on a wide range of topical skin care products (n = 15) and pro-
cedures (n = 3). We studied the three subgroups of topical skin
care products (see Types of interventions): no-rinse skin cleansers,
moisturisers, and skin protectants, either as separate products or
combined into one product. We also studies structured skin care
procedures.Nevertheless, the variation in products and procedures
did not allow us to pool data.
Almost half of the trials (n = 6) included participants with IAD as
well as without IAD at the start of the trial. We did not perform
a subgroup analysis. Consequently, we could not identify if the
tested skin care products and procedures performed as well in the
prevention as the treatment of IAD.
We found two ongoing studies (see Characteristics of ongoing
studies). The NCT02570139 2015 trial compares the use of two
film forming skin protectants, Cavilon AdvancedHigh Endurance
Skin Protectant and ConvaTec Sensi-Care Protective Barrier (n =
102). The outcomes measured in this trial are IAD severity, IAD
healing, pain due to IAD, and prevention of IAD development.
The NCT02690753 2016 trial compares a washcloth with cleans-
ing, moisturising and skin protecting properties (Comfort Shield
Barrier Cream Cloths) with standard care (n = 226) . The out-
comes measured include number of participants with IAD (new),
and comfort and tolerance of the participants. The reports of these
studies will be analysed for the next update of this review.
Quality of the evidence
A quantitative meta-analysis was not appropriate. We were unable
to pool the results from the different trials due to heterogeneity
in participant population, skin care products, skin care procedure,
outcomes, and measurement tools.
Almost all trials showed at least two sources of bias. Selective re-
porting of trial results was a less common source of bias and was
present in four trials (Anthony 1987; Brunner 2012; Dieter 2006;
Kennedy 1996), and unclear in one trial (Wang 2011). Lack of
blinding was the most common source of bias. Blinding of par-
ticipants and personnel was not possible in all but one trial due
to visual differences in the skin care products (Anthony 1987). In
only two trials (Cooper 2001; Buckley 2014), the outcome asses-
sors were blinded by using photographs. Another possible source
of bias was funding. At least five trials were funded by industry
(Baatenburg de Jong 2004; Buckley 2014; Byers 1995; Cooper
2001; Kennedy 1996). The overall risk of bias in the included
studies was high.
We could only perform a GRADE assessment of the quality of
evidence for two of the primary outcomes of this review, ‘number
of participants with IAD (new)’ and ‘number of participants with
IAD (residual, i.e. not healed)’; with six single studies. This was
due to a lack of statistical data (standard deviations, frequencies)
necessary to calculate risk ratios or mean differences. The results
from the GRADE assessment showed low to very low quality of
evidence for four trials, based on the risk of bias described above
(Anthony 1987; Brunner 2012; Cooper 2001; Lewis-Byers 2002).
Furthermore, the imprecision of the point estimates was serious
(large confidence intervals) as a consequence of small sample sizes.
Only the Beeckman 2011, and the Buckley 2014 studies showed
moderate quality evidence. The Beeckman 2011 trial was the only
trial which proved (post hoc) an adequate sample size to detect
real differences (statistical power).
As a conclusion, the quality of evidence for the prevention and
management of IAD was very low to moderate. All data should
be interpreted with caution.
Potential biases in the review process
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We performed a rigorous literature search to prevent missing rel-
evant trials. We searched the Cochrane Incontinence Group Spe-
cialised Trial Register, major databases, reference lists, and confer-
ence proceedings. In addition, we contacted specialists in the field
and all authors of the included studies. Furthermore, all review
authors are experts in the field, and performed multiple literature
reviews on healthcare subjects, and more specifically on the pre-
vention and treatment of IAD in adults. Finally, we only identified
three supplementary trials via reference lists. As a consequence, we
believe the possibility of missing any relevant trial was low.
The Cochrane Review protocol was written out and followed in
detail. All steps in the review process were performed by at least
two (independently working) researchers. In addition, the inter-
pretation of the findings was done by all review authors, working
in different countries around the globe. This minimised the risk
for errors, inaccuracies, and influences of individual interest. Fur-
thermore, experience was brought together.
The strict inclusion criteria limited the number of studies available
for inclusion. Many trials were not performed in adults, not ran-
domised, did not test topical skin care products or did not meet
the proposed outcomes. Whilst the inclusion criteria limited the
list of included studies, the studies with the strongest set-up were
used to draw conclusions.
Agreements and disagreements with other
studies or reviews
This review confirms the conclusions of two other systematic re-
views. Beeckman 2009 identified limited evidence for the effec-
tiveness of various interventions for the prevention and treatment
of IAD in adults. Furthermore, as in our Cochrane Review, soap
and water performed poorly in the prevention and treatment of
IAD. Similarly, the Corcoran 2013 study, which focused on trials
testing skin protectants, could not recommend any skin protec-
tant over another due to a lack of evidence. Both reviews identi-
fied the same weaknesses in trial design: absence of power calcula-
tions in advance, small sample sizes, no blinded assessments, and
short trial periods. Based on the findings of our review and the
Beeckman 2011 and Corcoran 2013 reviews, it is clear that the
available evidence on topical skin care products and procedures
for prevention and management of IAD in adults is limited. More
research to draw conclusions needs to be done.
The trials included in our review studied various topical skin care
products (skin cleansers and leave-on products) for the prevention
and treatment of IAD. Some commercial leave-on products seem
to perform better than others, but we could not identify which in-
gredients were responsible for this difference in effectiveness. Re-
cently Kottner andBeeckman published an overview of knowledge
and recommendations concerning IAD and pressure ulcers in geri-
atric patients (Kottner 2015). These authors combined research
findings with expert opinion. Kottner and Beeckman agreed with
the existence of various skin care products concerning IAD and
the lack of evidence on differences in benefits between products.
In addition, they described that the performance of leave-on prod-
ucts not only depends on individual ingredients but especially on
the combination of ingredients and the overall formulation. Fur-
thermore, in accordance with our finding that most trials made
no explicit distinction between the prevention and treatment of
IAD, Kottner and Beeckman described the absence of a technol-
ogy to promote skin barrier recovery after maceration in the el-
derly (Kottner 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is little evidence, of very low to moderate quality, on the
effectiveness of interventions for preventing and treating inconti-
nence-associated dermatitis (IAD) in adults. Consequently, it’s not
clear whether any leave-on product (moisturiser, skin protectant,
single or combined) performs better than another. Using a leave-
on product and avoiding soap is better than using nothing. The
performance of leave-on products depends on the combination of
ingredients, the overall formulation and the usage (e.g. amount
applied).
Implications for research
The current literature on interventions for preventing and treat-
ing IAD in adults consists of a few small trials of low to, at most,
moderate quality. None of the trials identified were comparable
in terms of trial set-up. In addition, the functioning of the tested
leave-on products was unclear (moisturising, skin protecting, or
both). Furthermore, we found no data on several participant-im-
portant outcomes.
Future trials should try to overcome the methodological weak-
nesses identified through this review. First of all, we recommend
the use of sample sizes large enough to reflect possible differences
in effectiveness of interventions. A priori sample size calculation is
mandatory. In addition, we recommend more efforts to blind the
outcome assessment and to use valid methods for randomisation
of participants and allocation concealment.
Researchers must report the results of their trials accurately and
according to CONSORT 2010. We identified a lack of reporting
of standard deviations, absolute frequencies, and levels of signifi-
cance (P values). These data are essential to adequately interpret
the research results and to compare outcomes across trials (e.g. in
a meta-analysis). Another consideration is the time of follow-up.
For interventions aimed at preventing IAD, we recommend a fol-
low-up period of at least six weeks, based on the time to develop
IADwhich is between one and 42 days (Bliss 2011). For interven-
tions aimed at treating IAD, we recommend a follow-up period
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of at least three weeks, based on the time to IAD-healing which is
between one and 19 days (Bliss 2011). High quality confirmatory
studies will enhance valuable conclusions about the effectiveness
of products and procedures to prevent and treat IAD. We further
recommend using standardised and comparable prevention and/
or treatment regimens in different settings/regions.
While performing our review, we determined that the function of
the skin care products (moisturising versus skin protecting) was
not always clear. To enhance the interpretation and comprehen-
sibility of the results of our Cochrane Review, we classified all
products not being a skin cleanser as leave-on products. The latter
group consisted of moisturisers and skin protectants, either as a
separate product or combined into one product. To enhance cor-
rect product selection and comparability in practice and research,
we highly recommend the use of a standardised language and ter-
minology in the description of skin care products.
There is a need for uniform, relevant, and participant-important
outcomes. Patients should be involved in the selection of these
outcomes, to enhance the contribution of trial results in informed
decision-making. Based on our experience with this Cochrane Re-
view, we recommend the development of a core set of outcomes.
This may improve the comparability of outcomes across stud-
ies. More comparability is important to be able to pool results.
Recently the IAD International Research Group has launched a
project which aims to develop a core outcome set of well-defined
IAD-related outcomes for clinical IAD research. This outcome
set will also include validated tools for outcome measurement
(Beeckman 2015a).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anthony 1987
Methods Randomised controlled trial
Participants 67 patients from different geriatric wards requiring diapers/pads
Exclusion criteria: Patients with a current acute illness
Age (median): 81 years
Gender (men/women): 10/54
Final analysis for development of IAD and reduction of erythema was on 57 patients
Group A: 29 (4 died, had an intercurrent illness or were discharged)
Group B: 28 (6 died, had an intercurrent illness or were discharged)
Final analysis for bacteriological counts was on 43 patients
Group A: 24 (5 incomplete bacteriological data)
Group B: 19 (9 incomplete tintometric/bacteriological data)
Interventions A: Sudocrem, liberal application with each diaper/pad change
B: Zinc oxide cream, liberal application with each diaper/pad change
Length of treatment: 14 days
Sudocrem consists of: 15.25% zinc oxide, 4.0% hydrous wool fat (hypoallergenic), 1.
01% benzyl benzoate, 0.15% benzyl cinnamate and 0.39% benzyl alcohol. The zinc
oxide cream consists of: 32.0% zinc oxide, 32.0% arachis oil, 0.045%calciumhydroxide,
0.5% oleic acid, 8% wool fat
Outcomes Number of participants with IAD (new)
Group A: 3/16; Group B: 2/11 (no significant difference between groups)
Reduction in erythema at day 7
Group A: 92.3%; Group B: 37.5% (P < 0.01)
Reduction of erythema at day 14
Group A: 84.6%; Group B: 50.0% (P < 0.01)
Corneocyte counts and parakeratotic cell ratios not reported
Bacteriological counts reduction
Greater reduction in bacteriological count in group A versus group B (P < 0.1)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Subjects were randomly allocated.
No further information is provided.
Allocation concealment (selection bias) Unclear risk No information provided.
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Anthony 1987 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk A double-blind controlled trial.
No further information is provided.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk A double-blind controlled trial.
No further information is provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk Not clear how patients were diagnosed with IAD, and
who did that
Main outcome measure is redness, given in percentages.
Not able to calculate number of patients with healing
Selective reporting (reporting bias) High risk One or more outcomes of interest in the review are re-
ported incompletely so that they cannot be entered in a
meta-analysis
Other bias Unclear risk Insufficient information to assess whether an important
risk of bias exists
Baatenburg de Jong 2004
Methods Randomised controlled trial
Participants 39 nursing home patients
Inclusion criteria: 18+ years; incontinent of urine, faeces or both; moderate to severe
redness ormoderate to severe erosionof the epidermiswithmild tomoderate involvement
of the dermis caused by urine, faeces or both in the perianal/buttocks area
Exclusion criteria: other significant skin disease or dermatological problem; medical
condition according to the investigators opinion; participation in another trial in the
previous 30 days
Group A: Not reported (mean age 83.3 years (SD 7.8); gender 60.0% female; mean
BMI 22.9 (SD 3.4))
Group B: Not reported (mean age 85.1 years (SD 7.2); gender 73.7% female; mean BMI
24.9 (SD 6.1))
10 patients terminated the study prematurely: 5 patients were healed, 4 died, 1 had high
fever and hypotension
Interventions Group A: Zinc oxide oil according to nursing home protocol; removal of remaining zinc
oxide every morning and evening before reapplication; reapplication if necessary during
diaper/pad change; use of diapers
Group B: Cavilon No Sting Barrier Film (3M) every 24, 48 to 72 hours depending on
skin condition and frequency of diaper change; use of diapers/pads
Length of treatment: 14 days
Outcomes Skin condition assessment score
Improvement in total skin damage score in favour of group B (P = 0.04)
Redness area
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Baatenburg de Jong 2004 (Continued)
Improved in group B compared to group A (no frequencies mentioned)
Reduction in redness severity
Group B: 47.4% versus 15.0%
Reduction in denudation area
Group B: 42.9 versus 16.7%
Reduction in denudation severity
Group B: 35.7% versus 8.3%
Product cost
Group A: EUR 14.16 (SD 1.83); Group B: EUR 7.55 (SD 8.60)
Nursing time
Group A: 208.95 minutes (SD 53.84); Group B: 161.96 minutes (SD 55.55)
Mean cost of nursing time
Group A: EUR 88.20 (SD 22.88); Group B: EUR 68.58 (SD 23.61)
Total cost (cost of treatment, cost of trial, cost of nursing)
Group A: EUR 102.96 (SD 23.25); Group B: EUR 76.13 (SD 25.48)
Incremental cost-effectiveness (ratio of difference inmean cost between groups andmean
change in skin condition on a 12-point scale)
Group A: EUR 98.06 (point improvement); Group B: EUR 28.36 (point improvement)
Notes Unclear in which group one patient dropped out.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised by computer.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding impossible because of difference in product ap-
pearance and use
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding, open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient not included in analysis. Reason not men-
tioned. 10 patients terminated the trial prematurely for
the following non-trial related reasons: healing (5), death
(4), high fever and hypotension (1)
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s pre-
specified outcomes that are of interest in the review have
been reported
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Baatenburg de Jong 2004 (Continued)
Other bias High risk Trial sponsored by 3M, whomakes Cavilon, who also did
the randomisation and data analysis. No mention of this
in the discussion, not clear how this may have influenced
results
Beeckman 2011
Methods Clustered randomised controlled trial
Participants 141 patients in 11 nursing home wards in 4 nursing homes at risk of/or affected by IAD
Inclusion criteria: chronically incontinent for urine, stool, or double urinary and faecal
incontinence and/or discolouration of the perineal kin, caused by urine or stool and not
caused by pressure/shear and/or hyperhydrated skin
Exclusion criteria: admitted to hospital or admitted from another nursing home ward
Group A: 73 (mean age 86.3 years; gender (male/female): 13/60; type of incontinence
(urine/faeces/both): 45/21/7)
Group B: 68 (mean age 85.9 years; gender (male/female): 15/53; type of incontinence
(urine/faeces/both): 39/21/8)
IAD prevalence and severity between groups not significantly different at baseline
Group A: 22.3%; Group B: 22.8% (P = 0.76)
IAD severity between groups not significantly different at baseline
Group A: 6.9/10; Group B: 7.3/10 (P = 0.99)
Interventions Group A: Daily use of cellulose fiber/polyester premoistened washcloth (Comfort Shield
Perineal Care Washcloth Dimethicone 3%, Sage Products Inc) for routine perineal skin
hygiene and after each diaper/pad change; no towel rubbing; in case of extremely soiled
skin soft washcloth and lukewarm water to remove soiling was allowed and a soft towel
to dry the skin; use of diapers/pads with frequency of change according to protocol of
the participant ward
Group B: Daily use of soft washcloth, water and soap (pH 6.5 to 7.5) for routine perineal
skin hygiene and after each diaper/pad change; no additional skin protectant was applied;
use of diapers/pads with frequency of change according to protocol of the participant
ward
Length of treatment: 120 days
Outcomes Number of patients with IAD (residual)
Group A: 8.1%; Group B: 27.1% (t = 6.3, P < 0.001)
IAD severity
Group A: 3.8/10; Group B: 6.4/10 (t = 3.1, P < 0.03)
Bacterial or fungal infection
Group A: 0; Group B: 0
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Beeckman 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Simple randomisation was used to assign the
wards to the experimental and control groups
(SPSS)
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants and personnel pos-
sible due to nature of intervention, i.e. washing
with a washcloth with cleansing, moisturising
and protecting properties or with soap and wa-
ter
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of participants and personnel pos-
sible due to nature of intervention, i.e. washing
with a washcloth with cleansing, moisturising
and protecting properties or with soap and wa-
ter
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No sufficient reporting of attrition/exclusions
to permit judgement
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s
prespecified outcomes that are of interest in the
review have been reported
Other bias Low risk
Brunner 2012
Methods Randomised controlled trial
Participants 64 hospitalised patients (critical and acute care)
Inclusion criteria: age > 18 years; incontinence; intact skin
Exclusion criteria: any erosion or sore on perineal skin; skin disease; known allergies
influencing skin integrity
Group A: 31 (mean age: 68.1 years; gender (male/female): 23/8)
Group B: 33 (mean age: 66.4 years; gender (male/female): 20/13)
Interventions Group A: No-rinse skin cleanser and moisturiser (Cavilon Skin Cleanser, 3M) and film-
forming skin product (Cavilon No Sting Barrier Film, 3M)
Group B: Cleanser, moisturiser, barrier washcloth (Comfort Shield Perineal Care Wash-
cloth Dimethicone 3%; Sage Products Inc)
Length of treatment: not reported
Outcomes Number of participants with intact skin
Group A: 24; Group B: 24
Number of participants with mild skin breakdown
Group A: 6; Group B: 5
42Interventions for preventing and treating incontinence-associated dermatitis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brunner 2012 (Continued)
Number of participants with moderate skin breakdown
Group A: 1; Group B: 4
Number of participants with severe skin breakdown
Group A: 0; Group B: 0
Time to skin breakdown
Group A: 213.3 hours; Group B: 91.1 hours (P = 0.045)
Cost per trial day
Group A: USD 6.59; Group B: USD 2.67 (P = 0.006)
Notes Time to skin breakdown was based on n = 6 in both groups, unclear why the analysis
was performed on 6 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported. Only mentioned randomly assigned.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition not reported, and no account of how missing
data were dealt with
Selective reporting (reporting bias) High risk P values not reported for Chi2 test.
Statistical methods unclear (was an F-test conducted?),
why were only n = 6 compared regarding average time for
skin breakdown, duration of intervention not reported
Other bias Unclear risk Compliance with the study protocol not controlled.
Buckley 2014
Methods Randomised controlled trial
Participants 142 hospitalised patients
Inclusion criteria: patients aged 12 years and older; urinary and/or faecal incontinence;
IAD ; no known allergies to treatment ingredients
Exclusion criteria: pre-existing pressure ulcer (grade 3 or 4) or other full thickness wound;
other skin condition that may affect healing; inclusion would affect medical care; treat-
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Buckley 2014 (Continued)
ment with IAD agents in previous week
Group A: 73 (mean age: 59.1 years (SD 15.7); gender (male/female): 21/52; BMI: 23.
7 (SD 5.5); diabetes: 18; bed bound: 70; IAD score (median; range): 5 (3-8))
Group B: 69 (mean age: 58.8 years (SD 19.7); gender (male/female): 16/53; BMI: 22.
8 (SD 5.1); diabetes: 15; bed bound: 68; IAD score (median; range): 6 (3-9))
Final analysis for change in IAD area affected was on 121 patients
Group A: 65 (discharged: 4; family withdrawal: 1; fungal infection or medical treatment:
3)
Group B: 56 (discharged: 7; no reason: 1; protocol deviation: 2; fungal infection or
medical treatment: 3)
Interventions Group A: 40% zinc oxide based paste (Desitin Max Strength Diaper Rash Paste) applied
twice daily and after incontinence episode; scrubbing and vigorous cleansing avoided; at
diaper/pad change IAD cleaned with plain saline, a polyhexanide wound cleaner, gauze
pads and soft tissue
Group B: 20% Zinc oxide based ointment (Calmoseptine ointment) applied twice daily
and after incontinence episode; scrubbing and vigorous cleansing avoided; at diaper/pad
change IAD cleaned with plain saline, a polyhexanide wound cleaner, gauze pads and
soft tissue
Length of treatment: 6 days
Outcomes Number of participants completely healed (intention-to-treat analysis)
Group A: 7; Group B: 15 (P = 0.046)
Number of participants completely healed (per-protocol analysis)
Group A: 7; Group B: 14 (P = 0.039)
Mean change in IAD area affected
Group A: -40.7 (SD 174.6); Group B: -136.6 (SD 114.2) (P = 0.001)
Fungal infection: 4
Notes No mention to which group the patients with fungal infection were allocated to
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer-generated.
Allocation concealment (selection bias) Low risk Treatment allocationwas assignedby the surgical research
unit, which was not linked to the trial team
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding for treatment not possible.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk High definition photographs were assessed by certified
wound care specialists, blinded to treatment allocation,
independent of sponsors and investigating team and not
involved in any other aspect of the study (p. 16)
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Buckley 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk Intention-to-treat analysis. All outcomes are reported.
Other bias Low risk
Byers 1995
Methods Cross-over trial
Participants 10 white female residents from a US nursing home
Inclusion criteria: intact perineal skin
Exclusion criteria: Thigh-level amputations, not expected to live through the duration
of the trial
Age (mean): 87 years
gender (male/female): 0/10
Brader score (mean): 9
Duration of incontinence (mean): 8 months
Final analysis for TEWL, erythema, pH and cleansing time was on 10 participants (1
transferred to other institution and 1 died)
Interventions Group A (baseline/control): soap (Liquid Dial Soap, The Dial Corp) and water
Group B (intervention): no-rinse skin cleanser (Triple Care Cleanser, Smith &Nephew)
Group C (intervention): no-rinse skin cleanser and skin protectant (Triple Care Cream,
Smith & Nephew)
Group D (intervention): soap and water and skin protectant
Group E (end/control): soap and water
In all groups use of diapers/pads, cleansing three times per day
Length of trial: 15 weeks, 3 weeks per group (each skin care procedure was applied in
each participant for three weeks, in random order)
Outcomes TEWL
Group B: 12.1; Group C: 12.8; Group D: 11.6; Group E: 15.7
Group E versus group B: P = 0.02
Group E versus group D: P = 0.01
Group E versus group C: P = 0.03
Erythema
Group C: 156 Group E: 192 (P = 0.014)
pH
Group A: 6.88; Group B: 7.18; Group C: 7.21; Group D: 7.29; Group E: 7.50
Group E versus group B: P = 0.006
Group E versus group C: P = 0.04
Group A versus group D: P = 0.002
Group A versus group C: P < 0.001
Cleansing time
Urine: No-rinse skin cleanser: 0.63 Soap and water: 4.50 (P < 0.001)
Stool and urine: No-rinse skin cleanser: 2.95 Soap and water: 12.6 (P < 0.001)
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Byers 1995 (Continued)
Notes No evidence of skin break down (IAD developing) in any patient
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Two residents were randomly assigned to each order (6 orders)
No more information is given.
Allocation concealment (selection bias) Unclear risk Two residents were randomly assigned to each order (6 orders)
No more information is given.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12 residents were initially selected, data from 10 residents were
available for analysis
1 resident was transferred to a nursing home closer to her family;
and 1 resident died of unrelated causes
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s prespecified
outcomes that are of interest in the review have been reported
Other bias High risk Cross-over design without washout periods.
’Compliance with regimen was controlled.’
Conley 2014
Methods Randomised controlled trial
Participants 99 residents from Progressive Care Unit
Inclusion criteria: age > 18 yrs; incontinence of urine and/or faeces; surgical patients
who had an indwelling urinary catheter for > 2 days; patients who had a urinary catheter
for any other length of time; patients with a rectal tube in situ for liquid stool
Exclusion criteria: Patients admitted from other units, outside facilities, or home
Group A: 55 (mean age: 75 years; gender (male/female): 32/23; incontinence (urinary/
bowel): 18/37; no dermatitis 20, mild/light red 22, moderate/red 5, severe/red 0; average
number of length of stay: 9.13 days; average Braden score: 15)
Group B: 44 (mean age: 67 years, gender (male/female): 19/25; incontinence (urinary/
bowel): 17/27; no dermatitis 12, mild/light red 15, moderate/red 6, severe/red 2; average
number of length of stay: 8.75 days; average Braden score: 14)
Differences: patients in group B were younger, but were more often affected by IAD and
showed higher severity. Group A had more patients receiving enteral nutrition (21.8%)
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than controls (5.5%) (P < 0.001); control group had more patients on pureed diet (23.
6%) than intervention group (3.6%) (P < 0.001); no significant difference reported for
other measures at baseline (e.g. serum albumin, Braden score)
Interventions Group A: skin care protocol performed every 6 hours and as needed
Group B: skin care protocol performed every 12 hours and as needed
Both groups: skin care protocol: gently skin cleansing with cleanser containing Aloe vera,
water, cleansing lotion; after cleansing skin was patted dry; if no erythema application
of a leave-on product including silicone; if erythema present application of a leave-on
product with including zinc oxide and menthol
Co-interventions: All nursing staff were given education on IAD and scoring erythema
Length of trial: 9 months
Outcomes No dermatitis
Group A: 43.6%; Group B: 40% (P = 0.718)
Mild/light red
Group A: 43.6%; Group B: 25.5% (P < 0.001)
Moderate/red
Group A: 7.1%; Group B: 10.9% (P < 0.001)
Severe/red
Group A: 1.9%; Group B: 1.8% (P = 0.898)
Notes Impossible to distinguish between prevention and treatment.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk To randomise the patients, those enrolled on even num-
bered days were put in the intervention group. Those
enrolled on odd numbered days were put in the control
group. Non-random component in the sequence gener-
ation process
Allocation concealment (selection bias) High risk Odd and even days used. Allocation can be foreseen.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, also not possible due to nature of interven-
tion: skin care every 12 or every 6 hours
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete data reported. Table with outcomes re-
ports same numbers at admission and discharge. 99 pa-
tients reported and 99 included
Patients were terminated from the trial upon transfer to
another unit, discharge home, discharge to another facil-
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Conley 2014 (Continued)
ity or death. Insufficient reporting of attrition/exclusions
to permit judgement
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s pre-
specified outcomes that are of interest in the review have
been reported
Other bias Unclear risk Insufficient information to assess whether an important
risk of bias exists
Cooper 2001
Methods Randomised Controlled Trial
Participants 93 elderly patients from elderly care homes and hospitals
Inclusion criteria: any patient suffering urinary incontinence, faecal incontinence, both,
catheterised and bypassing urine
Exclusion criteria: none described
Group A: 49 (median age: 79 years (IQR 73.5, 86.5); gender (male/female): 22/27;
nursing home residents/hospital patients: 28/21; median length of stay median: 0.38
years; healthy skin: 33; erythema: 9; broken skin: 5; average no. incontinence episodes
per 24 hours: 4; changes in mobility: 6)
Group B: 44 (median age: 85 years (IQR 79.8, 89.3); gender (male/female): 9/35;
nursing home residents/hospital patients: 20/24; median length of stay median: 1.72
years; healthy skin: 33; erythema: 5; broken skin: 3; average no. incontinence episodes
per 24 hours: 5; changes in mobility: 8)
Data complete for analysis on skin deterioration was on 87 patients. Gender difference
between groups (statistical significance not reported)
Interventions Group A: hospital soap (unperfumed and pH9.5-10.5 (1% aqueous solution)) and water
GroupB:Clinisan (Vernacare; skin cleanserwith pH5.5 - contains surfactant, emollients,
dimethicone, antibacterial agent, perfume)
Both groups: Other skin protectants stopped
Co-interventions: All nursing staff were given education by researcher
Length of follow-up: 10 months (follow-up 14 days)
Outcomes Number of patients with healthy skin
Group A: 17/46 (37%); Group B: 27/41 (66%)
Number of patients with deterioration of skin integrity
Group A: 14/46 (30%); Group B: 5/41 (12%)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Cooper 2001 (Continued)
Random sequence generation (selection
bias)
Low risk Patients were randomised by unmarked envelopes.
No further information is given.
Allocation concealment (selection bias) Unclear risk No clear description of concealment. No description of
envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not reported. Not possible due to differences in treat-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessment by two experts of outcomes using
photographs
Incomplete outcome data (attrition bias)
All outcomes
Low risk Six patients not included in analysis for the following
reasons: non-compliance (2), transfer to acute hospital
(1), application of skin protectants in error (2) and de-
velopment of superficial blistering on the tights (1)
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s pre-
specified outcomes that are of interest in the review
haven been reported
Other bias Low risk
Dieter 2006
Methods Randomised controlled trial
Participants 94 patients from 3 adult medical/surgical hospital units
Group A: 28; Group B: 35; Group C: 31
Interventions Group A: cleansing spray, washcloth, leave-on product
Group B: disposable washcloth with cleansing, moisturising and skin protecting prop-
erties (dimethicone)
Group C: disposable washcloth (discontinued at 4 weeks because of high rate of skin
problems (29%) per incontinent episode)
Outcomes Number of skin problems
Group A: 14; Group B: 18
Number of patients with skin problems
Group A: 6; Group B: 7
Average cost of treatment per patient
Group A: USD 6.13; Group B: USD 5.40
Notes Data extraction was based on an abstract. The authors did not respond to our request
for more details
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Based on the last digit of medical record number.
Allocation concealment (selection bias) High risk Based on the last digit of medical record number.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible due to visual differences between the inter-
ventions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition and exclusions not reported.
Selective reporting (reporting bias) High risk Trial protocol not available, abstract.
P values not reported.
Other bias Unclear risk Study described in an abstract, without sufficient details.
Kennedy 1996
Methods Randomised controlled Trial
Participants 40 subjects from health centre
Inclusion criteria: history of incontinence, urine, faeces or both; moderate skin break-
down
Exclusion criteria: not reported
Group A: 8
Group B: 8
Group C: 8
Group D: 8
Group E: 8
All patients: 40 (age: not reported; Gender (male/female): not reported; Type of incon-
tinence (urinary/faecal/both): 32/4/4; mean Braden score: 13.6 (SD 0.5); mean skin
condition score: 6.0 (SD 0.3))
No statistically significant differences regarding Braden mean score between groups; no
statistically significant differences regarding mean frequencies of incontinence episodes
between groups
Interventions Group A: received petrolatum ointment (Peri-Care, Sween) three times per day and as
necessary during 12 days
Group B: received zinc oxide cream (Baza, Sween) three times per day and as necessary
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during 12 days
Group C: received Cavilon No Sting Barrier Film (3M) every 24 hours during 12 days
Group D: received No Sting Barrier Film every 48 hours during 12 days
Group E: received No Sting Barrier Film every 72 hours during 12 days
Length of treatment: six months
Outcomes Skin condition score
Skin condition scores decreased in all five groups (Figure 5, page 69)
“There were no significant differences in skin condition among the five treatment groups
at any time during the trial” (page 69)
Amount of product use per day
Group A: 13.6 g (SD 1.9); Group B: 16.1 g (SD 2.2); Group C: one applicator per
patient per application; Group D: one applicator per patient per application; Group E:
one applicator per patient per application
Cost per day
Group A: USD 0.8; Group B: USD 1.2; Group C: USD 2.3; GroupD: USD 1.1; Group
E: USD 0.8
Notes Funding 3M Healthcare (Cavilon NSBF).
Skin condition scores difficult to interpret.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random assignment. No further information provided.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
Blinding not possible due to difference in products.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No incomplete data reported, insufficient reporting of
attrition/exclusion
Selective reporting (reporting bias) High risk One or more outcomes of interest in the review are re-
ported incompletely so that they cannot be entered in a
meta-analysis. Only average scores are mentioned
Trial protocol not published.
Other bias Unclear risk Funded by 3M Healthcare.
51Interventions for preventing and treating incontinence-associated dermatitis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lewis-Byers 2002
Methods Randomised Controlled Trial
Participants 31 nursing home residents
Inclusion criteria: incontinent for urine, stool or both
Exclusion criteria: indwelling catheters
Group A: 18 (range age: 41-78; gender (male/female): 4/14; type of incontinence (urine/
faeces/both): 1/4/13; baseline skin condition rating normal skin: 15; redness, slight rash:
1; intense redness: 0; redness, small blisters: 2; skin erosion, loss of skin: 0)
GroupB: 14 (range age: 63-105; gender (male/female): 1/13; type of incontinence (urine/
faeces/both): 2/0/11; baseline skin condition rating normal skin: 9; redness, slight rash:
1; intense redness: 3; redness, small blisters: 0; skin erosion, loss of skin: 0)
Interventions Group A: cleansing with Cavilon Antiseptic SkinCleanser (3M); during first incontinent
episode per shift Cavilon Durable Barrier Cream (3M) was applied
GroupB: cleansingwith soap (liquid or bar) and disposable washcloth andwater followed
by application of a lotion
Both groups: cleansing after each incontinent episode
Length of treatment: 3 weeks
Outcomes Skin condition score
Group A: 0.28 (SD 0.83); Group B: 0.77 (SD 1.30); not statistically significant (P value
not reported)
Pain score
Group A: 0.11 (SD 0.47); Group B: 0.77 (SD 1.30); not statistically significant (P value
not reported)
Skin cleansing time including preparation
Group A: 5 minutes per cleansing; 41 minutes per day; Group B: 13 minutes per cleans-
ing; 120 minutes per day
Notes Means and standard deviations of skin conditions and pain scores identical in group 1
(Table 3, page 49). Unclear whether this is correct or a typing error
Time was measured for an unknown subset of residents and modelled
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Patients were randomly assigned. Residents in even
numbered rooms were assigned to the control group,
residents in odd numbered rooms were assigned to the
trial protocol
Allocation concealment (selection bias) High risk Not present.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding.
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Lewis-Byers 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One patient not included in analysis. Reason not men-
tioned. One patient terminated the trial prematurely as
result of regained continence
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the trial’s pre-
specified outcomes that are of interest in the review
haven been reported
Other bias Unclear risk Corresponding author was a member of the company
delivering the trial products
Schoonhoven 2015
Methods Clustered randomised controlled trial
Participants 500 nursing home residents; mean age 82.4 (SD 8.3); gender 71.0% female
Inclusion criteria: elderly residents receiving bathing assistance
Exclusion criteria: residents who showered or bathed in bath tub more than once a week;
too sick to participate
Group A: 290 (mean age 81.8 (SD 8.7); gender 70.7% female; BMI 25.4 kg/m² (SD 5.
4))
Group B: 210 (mean age 83.3 (SD 7.5); gender 71.4% female; BMI 25.4 kg/m² (SD 6.
0))
Final analysis was on 450 residents (Group A: 257; Group B 193)
Interventions Group A: Provision of bed bath with disposable wash cloths impregnated with lotion;
heated in microwave before use; no towel drying
Group B: Provision of daily bad bath using tap water, washbowls, soap (different types)
, wash gloves and towels
Length of treatment: 6 weeks
Outcomes Prevalence of any skin abnormalities
Group A: 72.7%; Group B: 77.6%
Treatment x time interaction P = 0.04
Prevalence of significant skin lesions
Group A: 36.0% Group B: 38.0%
Treatment x time interaction P = 0.82
Prevalence of resistance
Group A: 12.4%; Group B: 9.4%
Treatment x time interaction P = 0.71
Notes Outcomes were not of interest for this review.
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by independent statistician.
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible due to visual differences
between the interventions
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Analysis by blinded statistician.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear consideration of losses of follow-up.
denominator of prevalence of skin lesions n =
500 (table 3, page 116), but n = 50 were lost
during the study
Selective reporting (reporting bias) Low risk No selective reporting apparent.
Other bias Low risk
Wang 2011
Methods Randomised controlled trial
Participants 62 in hospital patients with faecal incontinence lasted for 6 to 21 days
Inclusion criteria: long-term immobilisation; aged more than 80 years old; faecal incon-
tinence with perianal skin damage
Group A: 31; Group B: 31
No differences between patients in the intervention and the control group at baseline
for age, gender and severity of patient’s condition
Interventions Group A: cleansing of the perianal region after bowel spray with Dermlin (advanced
wound healing product)
Group B: cleansing of the perianal region after bowel spray with Genetime (recombinant
human epidermal growth factor)
Length of treatment: observation of the results after five days of treatment
Outcomes Proportion of patients with IAD healed (predefined outcome)
Not clearly described, translation from Chinese
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear from Chinese translation.
Allocation concealment (selection bias) Unclear risk Unclear from Chinese translation.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible due to visual differences between the skin
care products
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear from Chinese translation.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear from Chinese translation.
Selective reporting (reporting bias) Unclear risk Unclear from the Chinese translation.
Other bias Unclear risk Unclear from the Chinese translation, rather short report
(two pages in the journal)
BMI: body mass index
IAD: incontinence-associated dermatitis
IQR: inter-quartile range
SD: standard deviation
SPSS: Statistical Package for the Social Sciences (IBM)
TEWL: trans-epidermal water loss
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Samarrai 2007 No topical skin care product studied: method for improving protocol compliance
Bates-Jensen 2003 No topical skin care products studied: an exercise and incontinence intervention
Bauer 2007 Report of a study protocol. Trial authors contacted for more information but no response received
Bennett 1998 No topical skin care products studied: low air loss hydrotherapy
Bliss 2007 No randomised controlled trial.
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Brown 1994 No topical skin care products studied: diapers and pads.
Dealey 1995 No randomised controlled trial: a preliminary trial.
Denat 2011 No topical skin care products studied: perianal pouch and adult containment brief
Fader 2003 No topical skin care products studied: absorbent pads.
Harries 2016 Study concerning the effectiveness of implementation strategies not effectiveness of products/procedures
Holroyd 2014 No randomised controlled trial: product evaluation by hospitals
Iraji 2003 Pediatric population.
James 1975 Pediatric population.
Kyung 2014 No randomised controlled trial: no random allocation of participants
Leiby 1994 No topical skin care products studied: reusable underpads.
Lyder 1992 No randomised controlled trial: no random allocation of participants
NCT02475512 2015 Study was finished prematurely, no reliable results possible
Netta-Turner 2008 No topical skin care products studied: rectal trumpet.
Pinedo 2012 No intervention for preventing or treating incontinence-associated dermatitis: intervention to decrease the
rate of faecal incontinence
Pittman 2012 No topical skin care products studied: bowel management system catheter, rectal/nasopharyngeal trumpet
Shin 2012 No topical skin care products studied: uncoated paper.
Su 2015 No topical skin care products studied: suspension positioning system
Sugama 2012 No topical skin care products studied: improved absorbent pad
Zehrer 2004 No randomised controlled trial: descriptive trial.
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Characteristics of studies awaiting assessment [ordered by study ID]
Kajii 2005
Methods Clustered randomised controlled trial
Participants 101 elderly from 5 hospitals and health care facilities for elderly, who used a diaper for their incontinence
Age (average): 84.9
Interventions Group A: skin protection cleaning foam 2 times per day
Group B: skin protection cleaning foam 4 times per day
Group C: conventional care using warm water
Length of treatment: 6 days
Outcomes The amount of moisture
Group A: 53.6 (SD 10.0)
Group B: 70.5 (SD 9.1)
Group C: 49.7 (SD 7.2)
The amount of sebum
Group A: 2.1 (SD 3.1)
Group B: 5.0 (SD 5.4)
Group C: 1.5 (SD 1.5)
Notes A translation is awaited.
The outcomes reported were not of interest for this review.
SD: standard deviation
Characteristics of ongoing studies [ordered by study ID]
NCT02570139 2015
Trial name or title Clinical Study to Assess a New Barrier Film’s Ability to Provide Skin Protection Against Incontinence &Allow
Healing
Methods Randomised controlled trial
Participants 102 patients
admitted to a nursing care facility, with
severe Category 2 Incontinence-Associated Dermatitis - red with skin breakdown (i.e. skin erosion and
denudation or denudation of skin alone)?
Age: 36 weeks (or greater gestational age) or older
Interventions Group A: Cavilon Advanced High Endurance Skin Protectant Product applied 3x/per week
Group B: ConvaTec Sensi-Care Protective Barrier applied following manufacturer’s recommendation
Length of treatment: 21 days depending on length of hospitalisation
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Outcomes Reduction in dermatitis scores
Re-epithelialization to a category 1 or lower
Reduction in pain scores
Prevention of IAD
Starting date October 2016
Contact information Mary Mathisen, BS
Bruce Ekholm, MS
Notes
NCT02690753 2016
Trial name or title Pressure Ulcer Prevention: a Turn and Positioning System Combined With Incontinence Care and Tailored/
Standard Repositioning
Methods Randomised controlled trial
Participants 226 patients at risk of developing pressure ulcers (Braden < 17), free of pressure ulcers category II, III, IV and
IAD category 2 at the start of the study
Age: 18 years and older
Interventions Group A: a repositioning protocol tailored to individual risk factors, use of the Prevalon Turn and Position
System 2.0 Device (for turning and positioning patients at risk when laying in bed). and use of Comfort
Shield Barrier Cream Cloths (for incontinence care every morning and after each episode of incontinence)
GroupB: standard repositioning, use of the PrevalonTurn and Position System2.0Device. and use of Comfort
Shield Barrier Cream Cloths
Group C: usual care
Length of treatment: 8 days
Outcomes Turning compliance of nurses
Turning angle
Sacrum free of pressure
Incidence of pressure ulcers and incontinence-associated dermatitis
Comfort and preferences of the caregiver
Comfort and tolerance of the patient
Cost-effectiveness of the prevention of pressure ulcers
Starting date February 2016
Contact information Dimitri Beeckman, PhD
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Any topical skin care product versus another topical skin care product
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
IAD (residual, i.e. not healed)
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 No-rinse skin cleanser and
skin cream (A) versus soap and
water and lotion (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Desitin (A) versus
Calmoseptine (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Number of participants with
IAD (new)
3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Skin cleanser (A) versus
soap and water (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Sudocrem (A) versus zinc
oxide cream (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 No-rinse skin cleanser/
moisturiser and film-forming
skin product (A) versus
cleansing/moisturising/skin
protecting washcloth (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Surface affected by IAD
(measurement of size of lesion)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Desitin (A) versus
Calmoseptine (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Staff time 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Skin cleanser/moisturiser
(A) versus soap and water (B)
(urine)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Skin cleanser/moisturiser
(A) versus soap and water (B)
(urine and stool)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 No-rinse skin cleanser and
a skin cream (A) versus soap
and water and a lotion (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Number of participants with
IAD completely healed
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Desitin (A) versus
Calmoseptine (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 IAD severity 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Sudocrem (A) versus zinc
oxide cream (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 No-rinse skin cleanser and
skin cream (A) versus soap and
water and lotion (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.3 Zinc oxide cream (A)
versus petrolatum ointment (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Zinc oxide cream (A)
versus film-forming skin
product (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 Petrolatum ointment
(A) versus film-forming skin
product (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Any skin care procedure (method or frequency of application) versus any unstructured skin care
procedure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants with
IAD (residual, i.e. not healed)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Washcloth with cleansing,
moisturising, and protecting
properties (A) versus water and
pH neutral soap (B)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 IAD Severity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Washcloth with cleansing,
moisturising, and protecting
properties (A) versus water and
pH neutral soap (B)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 1 Number of participants with IAD (residual, i.e. not healed).
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 1 Number of participants with IAD (residual, i.e. not healed)
Study or subgroup Group A Group B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 No-rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)
Lewis-Byers 2002 2/18 4/13 0.36 [ 0.08, 1.68 ]
2 Desitin (A) versus Calmoseptine (B)
Buckley 2014 66/73 54/69 1.16 [ 1.00, 1.34 ]
0.001 0.01 0.1 1 10 100 1000
Favours Group A Favours Group B
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Analysis 1.2. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 2 Number of participants with IAD (new).
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 2 Number of participants with IAD (new)
Study or subgroup Group A Group B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin cleanser (A) versus soap and water (B)
Cooper 2001 6/33 15/32 0.39 [ 0.17, 0.87 ]
2 Sudocrem (A) versus zinc oxide cream (B)
Anthony 1987 3/16 2/11 1.03 [ 0.20, 5.19 ]
3 No-rinse skin cleanser/moisturiser and film-forming skin product (A) versus cleansing/moisturising/skin protecting washcloth (B)
Brunner 2012 7/31 9/33 0.83 [ 0.35, 1.95 ]
0.002 0.1 1 10 500
Favours Group A Favours Group B
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Analysis 1.3. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 3 Surface affected by IAD (measurement of size of lesion).
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 3 Surface affected by IAD (measurement of size of lesion)
Study or subgroup Desitin Calmoseptine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Desitin (A) versus Calmoseptine (B)
Buckley 2014 65 163.7 (144.4) 56 82.1 (111.9) 81.60 [ 35.87, 127.33 ]
-200 -100 0 100 200
Favours Desitin Favours Calmoseptine
Analysis 1.4. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 4 Staff time.
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 4 Staff time
Study or subgroup Group A Group B
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Skin cleanser/moisturiser (A) versus soap and water (B) (urine)
Byers 1995 6 0.63 (0.21) 6 4.5 (0.51) -3.87 [ -4.31, -3.43 ]
2 Skin cleanser/moisturiser (A) versus soap and water (B) (urine and stool)
Byers 1995 6 2.95 (1.16) 6 12.63 (2.26) -9.68 [ -11.71, -7.65 ]
3 No-rinse skin cleanser and a skin cream (A) versus soap and water and a lotion (B)
Lewis-Byers 2002 18 41 (0) 13 120 (0) Not estimable
-10 -5 0 5 10
Favours Group A Favours Group B
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Analysis 1.5. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 5 Number of participants with IAD completely healed.
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 5 Number of participants with IAD completely healed
Study or subgroup Desitin Calmoseptine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Desitin (A) versus Calmoseptine (B)
Buckley 2014 7/73 15/69 0.44 [ 0.19, 1.02 ]
0.001 0.01 0.1 1 10 100 1000
Favours Calmoseptine Favours Desitin
Analysis 1.6. Comparison 1 Any topical skin care product versus another topical skin care product,
Outcome 6 IAD severity.
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 1 Any topical skin care product versus another topical skin care product
Outcome: 6 IAD severity
Study or subgroup Group A Group B
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Sudocrem (A) versus zinc oxide cream (B)
Anthony 1987 29 0 (0) 28 0 (0) Not estimable
2 No-rinse skin cleanser and skin cream (A) versus soap and water and lotion (B)
Lewis-Byers 2002 18 0.28 (0.83) 13 0.77 (1.3) -0.49 [ -1.29, 0.31 ]
3 Zinc oxide cream (A) versus petrolatum ointment (B)
Kennedy 1996 8 0 (0) 8 0 (0) Not estimable
4 Zinc oxide cream (A) versus film-forming skin product (B)
Kennedy 1996 8 0 (0) 8 0 (0) Not estimable
5 Petrolatum ointment (A) versus film-forming skin product (B)
Kennedy 1996 8 0 (0) 8 0 (0) Not estimable
-4 -2 0 2 4
Favours Group A Favours Group B
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Analysis 2.1. Comparison 2 Any skin care procedure (method or frequency of application) versus any
unstructured skin care procedure, Outcome 1 Number of participants with IAD (residual, i.e. not healed).
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure
Outcome: 1 Number of participants with IAD (residual, i.e. not healed)
Study or subgroup Group A Group B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B)
Beeckman 2011 5/63 15/58 0.31 [ 0.12, 0.79 ]
0.001 0.01 0.1 1 10 100 1000
Favours Group A Favours Group B
Analysis 2.2. Comparison 2 Any skin care procedure (method or frequency of application) versus any
unstructured skin care procedure, Outcome 2 IAD Severity.
Review: Interventions for preventing and treating incontinence-associated dermatitis in adults
Comparison: 2 Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure
Outcome: 2 IAD Severity
Study or subgroup Group A Group B
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Washcloth with cleansing, moisturising, and protecting properties (A) versus water and pH neutral soap (B)
Beeckman 2011 66 3.9 (1.4) 61 6.4 (2.4) -2.50 [ -3.19, -1.81 ]
-4 -2 0 2 4
Favours Group A Favours Group B
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A P P E N D I C E S
Appendix 1. Cochrane Incontinence Group Speciailsed Register search strategy
We used the following terms to search the Cochrane Incontinence Group Specialised Register:
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({TOPIC.URINE.INCON.Skin*} OR {TOPIC.FAECAL.INCON.Skin*}))
All searches were of the keyword field of Reference Manager 2012. The date of the last search was 28 September 2016.
Appendix 2. CENTRAL, MEDLINE and MEDLINE In-Process search strategy
Cochrane Central Register of Controlled Trials April 2015, Ovid MEDLINE(R) 1946 to May Week 3 2015, Ovid MEDLINE(R)
In-Process & Other Non-Indexed Citations 26 May 2015 on OvidSP were searched on 27 May 2015 using the following search:
1. controlled clinical trial.pt.
2. randomized controlled trial.pt.
3. randomized controlled trials/
4. random allocation/
5. double blind method/
6. single blind method/
7. clinical trial.pt.
8. exp clinical trial/
9. placebos/
10. placebo$.tw.
11. random$.tw.
12. research design/
13. volunteer$.tw.
14. (clin$ adj25 trial$).tw.
15. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
16. factorial.tw.
17. cross-over studies/
18. crossover.tw.
19. latin square.tw.
20. (balance$ adj2 block$).tw.
21. trial.ti.
22. (animals not humans).sh.
23. or/1-21
24. 23 not 22
25. (incontinen* adj25 dermatitis).tw.
26. (incontinen* adj25 skin).tw.
27. exp dermatological agents/ and Pressure Ulcer/
28. (incontinen* adj2 lesion*).tw.
29. (moisture adj2 lesion*).tw.
30. (macerat* adj2 skin*).tw.
31. (perine* adj2 dermatitis).tw.
32. Diaper Rash/
33. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. 33 and 24
35. dermatitis/ or dermatitis, contact/ or dermatitis, irritant/ or diaper rash/ or erythema/
36. Pressure Ulcer/
37. skin integrity.tw.
38. skin inflam*.tw.
39. (skin adj2 loss*).tw.
40. (skin adj2 red*).tw.
41. (skin adj2 blister*).tw.
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42. (skin adj2 bull*).tw.
43. (skin adj2 perine*).tw.
44. erythema*.tw.
45. (skin adj2 (erod* or erosion*)).tw.
46. (skin adj2 barrier*).tw.
47. secondary skin infect*.tw.
48. (cutaneous adj2 loss*).tw.
49. (cutaneous adj2 (red* or blister* or bull* or perine* or barrier* or loss* or inflam* or integrity)).tw.
50. (epiderm* adj2 loss*).tw.
51. (epiderm* adj2 (red* or blister* or bull* or perine* or barrier* or loss* or inflam* or integrity)).tw.
52. (skin adj2 rash*).tw.
53. (rash* adj2 (epiderm* or cutaneous or cuticle)).tw.
54. (dermatit* adj2 (contact or irrit*)).tw.
55. (skin adj2 damag*).tw.
56. (skin adj2 lesion*).tw.
57. Perineum/
58. perirect*.tw.
59. perianal.tw.
60. buttocks/ or thigh/
61. intergluteal.tw.
62. perigenital.tw.
63. perine*.tw.
64. inguinal.tw.
65. Intertrigo/
66. (buttock* or thigh*).tw.
67. genital*.tw.
68. intertrig*.tw.
69. genitalia/ or genitalia, female/ or vulva/ or genitalia, male/ or scrotum/
70. vulva*.tw.
71. scrot*.tw.
72. (labium or labia).tw.
73. heat rash*.tw.
74. (heat adj2 rash*).tw.
75. Dermatitis, Allergic Contact/
76. ((diaper* or napkin* or nappy or nappies or perine*) adj2 (dermat* or erythema* or rash* or wet*)).tw.
77. (moist* adj2 (sore* or ulcer* or damag* or wound* or injur* or lesion* or skin)).tw.
78. ((decubitus or pressure or bed) adj2 (sore* or ulcer*)).tw.
79. bedsore*.tw.
80. or/35-79
81. 24 and 80
82. exp Skin Care/
83. hygiene/
84. dermatologic agents/ or zinc oxide/ or emollients/ or mineral oil/ or petrolatum/ or simethicone/
85. surface-active agents/ or soaps/
86. Ointments/
87. exp Detergents/
88. pharmaceutic aids/ or ointment bases/ or petrolatum/ or pharmaceutical vehicles/ or propylene glycol/
89. pharmaceutical vehicles/ or propylene glycol/ or excipients/ or octoxynol/ or poloxamer/ or polysorbates/ or tragacanth/ or
tromethamine/
90. skincar*.tw.
91. skin care.tw.
92. (skin adj2 (regime* or protocol* or program*)).tw.
93. (skin adj2 clean*).tw.
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94. (skin adj2 moistur*).tw.
95. (skin adj2 protect*).tw.
96. (moisture adj2 barrier*).tw.
97. (skin adj2 (product or products)).tw.
98. (perine* adj2 clean*).tw.
99. washcloth*.tw.
100. barrier cloth*.tw.
101. (wash adj2 cloth*).tw.
102. exp Oils/
103. (skin adj2 (health or integrity or restor* or maintain*)).tw.
104. (skin adj2 manag*).tw.
105. Baths/
106. (skin adj2 wash*).tw.
107. shower*.tw.
108. or/82-107
109. 81 and 108
110. 34 or 109
111. remove duplicates from 110
112. cochrane incontinence group.gc.
113. 111 not 112
Appendix 3. CINAHL search strategy
CINAHL (on EBSCO) covering from inception (December 1981) to 20150527 (entry date) was searched on 28 May 2015 using the
following search strategy:
# Query
S112 S27 OR S41 OR S111
S111 S23 AND S83 AND S110
S110 S84 OR S85 OR S86 OR S87 OR S88 OR S89 OR S90 OR S91 OR S92 OR S93 OR S94 OR S95 OR S96 OR S97 OR
S98 OR S99 OR S100 OR S101 OR S102 OR S103 OR S104 OR S105 OR S106 OR S107 OR S108 OR S109
S109 AB shower*
S108 TI shower*
S107 (MH “Bathing and Baths”) OR (MH “Self-Care Assistance: Bathing-Hygiene (Iowa NIC)”) OR (MH “Bathing-Hygiene Self
Care Deficit (NANDA)”) OR (MH “Bathing-Hygiene Deficit (Saba CCC)”) OR (MH “Self-Care: Bathing (Iowa NOC)”)
OR (MH “Bathing (Iowa NIC)”)
S106 (MH “Oils+”)
S105 AB wash N2 cloth*
S104 TI wash N2 cloth*
S103 AB barrier N2 cloth*
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(Continued)
S102 TI barrier N2 cloth*
S101 AB washcloth*
S100 TI washcloth*
S99 AB perine* N2 clean*
S98 TI perine* N2 clean*
S97 AB moisture N2 barrier*
S96 TI moisture N2 barrier*
S95 AB skin N2 regime* OR skin N2 protocol* OR skin N2 program* OR skin N2 clean* OR skin N2 moistur* OR skin N2
protect* OR skin N2 product OR skin N2 products OR skin N2 health OR skin N2 integrity OR skin N2 restor* OR skin
N2 maintain* OR skin N2 manag* OR skin N2 wash*
S94 TI skin N2 regime* OR skin N2 protocol* OR skin N2 program* OR skin N2 clean* OR skin N2 moistur* OR skin N2
protect* OR skin N2 product OR skin N2 products OR skin N2 health OR skin N2 integrity OR skin N2 restor* OR skin
N2 maintain* OR skin N2 manag* OR skin N2 wash*
S93 AB skin care
S92 TI skin care
S91 AB skincare
S90 TI skincare
S89 (MH “Propylene Glycols+”)
S88 (MH “Creams”) OR (MH “Ointments”) OR (MH “Liniments”)
S87 (MH “Surface-Active Agents+”)
S86 (MH “Dermatologic Agents+”)
S85 (MH “Hygiene”) OR (MH “Self-Care Assistance: Bathing-Hygiene (Iowa NIC)”) OR (MH “Bathing-Hygiene Self Care
Deficit (NANDA)”) OR (MH “Bathing-Hygiene Deficit (Saba CCC)”) OR (MH “Self-Care: Hygiene (Iowa NOC)”)
S84 (MH “Skin Care”) OR (MH “Skin Care (Saba CCC)”) OR (MH “Skin Care: Topical Treatments (Iowa NIC)”) OR (MH
“Perineal Care”)
S83 S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR
S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62 OR S63 OR S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR
S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81 OR S82
S82 AB bed N2 sore* OR bed N2 ulcer*
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(Continued)
S81 TI bed N2 sore* OR bed N2 ulcer*
S80 AB pressure N2 sore* OR pressure N2 ulcer*
S79 TI pressure N2 sore* OR pressure N2 ulcer*
S78 AB decubitus N2 sore* OR decubitus N2 ulcer*
S77 TI decubitus N2 sore* OR decubitus N2 ulcer*
S76 AB moist* N2 sore* OR moist* N2 ulcer* OR moist* N2 damag* OR moist* N2 wound* OR moist* N2 injur* OR moist*
N2 lesion* OR moist* N2 skin
S75 TI moist* N2 sore* OR moist* N2 ulcer* OR moist* N2 damag* OR moist* N2 wound* OR moist* N2 injur* OR moist*
N2 lesion* OR moist* N2 skin
S74 AB perine* N2 rash* OR perine* N2 wet*
S73 TI perine* N2 rash* OR perine* N2 wet*
S72 AB nappies N2 dermatit* OR nappies N2 rash* OR nappies N2 wet*
S71 TI nappies N2 dermatit* OR nappies N2 rash* OR nappies N2 wet*
S70 AB nappy N2 dermatit* OR nappy N2 rash* OR nappy N2 wet*
S69 TI nappy N2 dermatit* OR nappy N2 rash* OR nappy N2 wet*
S68 AB napkin* N2 dermatit* OR napkin* N2 rash* OR napkin* N2 wet*
S67 TI napkin* N2 dermatit* OR napkin* N2 rash* OR napkin* N2 wet*
S66 AB diaper* N2 dermatit* OR diaper* N2 rash* OR diaper N2 wet*
S65 TI diaper* N2 dermatit* OR diaper* N2 rash* OR diaper N2 wet*
S64 AB bedsore*
S63 TI bedsore*
S62 AB rash* N2 heat
S61 TI rash* N2 heat
S60 AB dermatit* N2 contact OR dermatit* N2 contact
S59 TI dermatit* N2 contact OR dermatit* N2 contact
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(Continued)
S58 AB rash* N2 cuticle
S57 TI rash* N2 cuticle
S56 AB epiderm* N2 loss* OR epiderm* N2 red* OR epiderm* N2 blister* OR epiderm* N2 bull* OR epiderm* N2 perine*
OR epiderm* N2 barrier* OR epiderm* N2 loss* OR epiderm* N2 inflam* OR epiderm* N2 integrity OR epiderm* N2
rash*
S55 TI epiderm* N2 loss* OR epiderm* N2 red* OR epiderm* N2 blister* OR epiderm* N2 bull* OR epiderm* N2 perine* OR
epiderm* N2 barrier* OR epiderm* N2 loss* OR epiderm* N2 inflam* OR epiderm* N2 integrity OR epiderm* N2 rash*
S54 AB cutaneous N2 loss* OR cutaneous N2 red* OR cutaneous N2 blister* OR cutaneous N2 bull* OR cutaneous N2 perine*
OR cutaneous N2 barrier* OR cutaneous N2 loss* OR cutaneous N2 inflam* OR cutaneous N2 integrity OR cutaneous
N2 rash*
S53 TI cutaneous N2 loss* OR cutaneous N2 red* OR cutaneous N2 blister* OR cutaneous N2 bull* OR cutaneous N2 perine*
OR cutaneous N2 barrier* OR cutaneous N2 loss* OR cutaneous N2 inflam* OR cutaneous N2 integrity OR cutaneous
N2 rash*
S52 AB erythema*
S51 TI erythema*
S50 AB skin N2 loss* OR skin N2 red* OR skin N2 blister* OR skin N2 bull* OR skin N2 perine* OR skin N2 erod* OR skin
N2 erosion* OR skin N2 barrier* OR skin N2 rash* OR skin N2 damag* OR skin N2 lesion*
S49 TI skin N2 loss* OR skin N2 red* OR skin N2 blister* OR skin N2 bull* OR skin N2 perine* OR skin N2 erod* OR skin
N2 erosion* OR skin N2 barrier* OR skin N2 rash* OR skin N2 damag* OR skin N2 lesion*
S48 AB skin N2 inflam*
S47 TI skin N2 inflam*
S46 AB skin N2 integrity
S45 TI skin N2 integrity
S44 AB pressure N2 ulcer
S43 TI pressure N2 ulcer
S42 (MH “Pressure Ulcer”) OR (MH “Pressure Ulcer Stage 4 Care (Saba CCC)”) OR (MH “Pressure Ulcer Stage 3 Care (Saba
CCC)”) OR (MH “Pressure Ulcer Stage 2 Care (Saba CCC)”) OR (MH “Pressure Ulcer Stage 1 Care (Saba CCC)”) OR
(MH “Pressure Ulcer Care (Saba CCC)”) OR (MH “Pressure Ulcer Prevention (Iowa NIC)”) OR (MH “Pressure Ulcer Care
(Iowa NIC)”)
S41 S23 AND S40
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(Continued)
S40 S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39
S39 AB perine* N2 dermatitis*
S38 TI perine* N2 dermatitis*
S37 AB macerat* N2 skin*
S36 TI macerat* N2 skin*
S35 AB moisture N2 lesion*
S34 TI moisture N2 lesion*
S33 AB incontinen* N2 lesion*
S32 TI incontinen* N2 lesion*
S31 AB incontinen* N25 skin
S30 TI incontinen* N25 skin
S29 AB incontinen* N25 dermatitis
S28 TI incontinen* N25 dermatitis
S27 S23 AND S26
S26 S24 OR S25
S25 (MH “Diaper Rash”)
S24 (MH “Dermatitis, Perineal”)
S23 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19
or S20 or S21 or S22
S22 TI ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25 blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl*
N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* ) or AB ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25
blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl* N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* )
S21 (MH “Comparative Studies”)
S20 (MH “Clinical Research+”)
S19 (MH “Static Group Comparison”)
S18 (MH “Quantitative Studies”)
71Interventions for preventing and treating incontinence-associated dermatitis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
S17 (MH “Crossover Design”) or (MH “Solomon Four-Group Design”)
S16 (MH “Factorial Design”)
S15 (MH “Community Trials”)
S14 (MH “Random Sample”)
S13 TI balance* N2 block* or AB balance* N2 block*
S12 TI “latin square” or AB “latin square”
S11 TI factorial or AB factorial
S10 TI clin* N25 trial* or AB clin* N25 trial*
S9 (MH “Study Design”)
S8 (AB random*) OR (TI random*)
S7 (AB placebo*) OR (TI placebo*)
S6 (MH “Placebos”)
S5 (PT Clinical Trial) OR (PT “randomized controlled trial”)
S4 (MH “Clinical Trials+”)
S3 MH (random assignment) OR (crossover design)
S2 cross-over
S1 crossover
Appendix 4. Web of Science (WoS) search strategy
Web of Science (on Web of Knowledge) - covering from inception of each component database to the most recent records available
- was searched on 28 May 2015 using the search strategy given below. The search was limited to the WoS Core Collection
Set
#42 #40 OR #22
Refined by: Databases: ( WOS )
Timespan=All years
Search language=Auto
72Interventions for preventing and treating incontinence-associated dermatitis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#41 #40 OR #22
Timespan=All years
Search language=Auto
#40 #39 AND #33 AND #5
DocType=All document types; Language=All languages;
#39 #38 OR #37 OR #36 OR #35 OR #34
DocType=All document types; Language=All languages;
#38 TOPIC: (Oils or bath*OR shower*ORhygieneOR zinc oxideOR emollientsORmineral oil OR petrolatumOR simethicone
OR soap* OR ointment* OR detergent*)
DocType=All document types; Language=All languages;
#37 TOPIC: ((wash OR barrier) NEAR/2 cloth)
DocType=All document types; Language=All languages;
#36 TOPIC: (washcloth* OR skincar*)
DocType=All document types; Language=All languages;
#35 TOPIC: ((skin NEAR/2 (care OR regime* OR protocol* OR program* OR clean* OR moistur* OR protect* OR product
OR products OR health OR integrity OR restor* OR maintain* OR manag* OR wash*)))
DocType=All document types; Language=All languages;
#34 TOPIC: (perine* NEAR/2 clean*)
DocType=All document types; Language=All languages;
#33 #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR #24 OR #23
DocType=All document types; Language=All languages;
#32 TOPIC: (bedsore*)
DocType=All document types; Language=All languages;
#31 TOPIC: ((decubitus OR pressurre OR bed) NEAR/2 (sore* OR ulcer*))
DocType=All document types; Language=All languages;
#30 TOPIC: (moist* NEAR/2 (sore* OR ulcer* OR damag* OR wound* OR injur* OR lesion* or skin))
DocType=All document types; Language=All languages;
#29 TOPIC: ((diaper* OR napkin* OR nappy OR nappies OR perine*) NEAR/2 (dermat* OR erythema* OR rash* OR wet*))
DocType=All document types; Language=All languages;
#28 TOPIC: (dermatit* NEAR/2 (contact OR irrit*))
DocType=All document types; Language=All languages;
#27 TOPIC: (rash* NEAR/2 (epiderm* OR cutaneous OR cuticle))
DocType=All document types; Language=All languages;
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(Continued)
#26 TOPIC: (erythema*)
DocType=All document types; Language=All languages;
#25 TOPIC: (epiderm* NEAR/2 (integrity OR inflam* OR loss* OR red* OR blister* OR bull* OR perine* OR erod* OR
erosion* OR barrier* OR rash* OR lesion* OR damag*))
DocType=All document types; Language=All languages;
#24 TOPIC: (cutaneous NEAR/2 (integrity OR inflam* OR loss* OR red* OR blister* OR bull* OR perine* OR erod* OR
erosion* OR barrier* OR rash* OR lesion* OR damag*))
DocType=All document types; Language=All languages;
#23 TOPIC: (skin NEAR/2 (integrity OR inflam* OR loss* OR red* OR blister* OR bull* OR perine* OR erod* OR erosion*
OR barrier* OR rash* OR lesion* OR damag*))
DocType=All document types; Language=All languages;
#22 #21 AND #5
DocType=All document types; Language=All languages;
#21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
DocType=All document types; Language=All languages;
#20 TOPIC: (diaper rash)
DocType=All document types; Language=All languages;
#19 TOPIC: (perine* NEAR/2 dermatitis*)
DocType=All document types; Language=All languages;
#18 TOPIC: (macerat* NEAR/2 skin*)
DocType=All document types; Language=All languages;
#17 TOPIC: (moisture NEAR/2 lesion*)
DocType=All document types; Language=All languages;
#16 TOPIC: (incontinen* NEAR/2 lesion*)
DocType=All document types; Language=All languages;
#15 TOPIC: (dermatological AND (pressure near/2 ulcer*))
DocType=All document types; Language=All languages;
#14 TOPIC: (emollient* AND decubit*)
DocType=All document types; Language=All languages;
#13 TOPIC: ((mineral near/2 oil*) AND decubit*)
DocType=All document types; Language=All languages;
#12 TOPIC: (dermatological AND decubit*)
DocType=All document types; Language=All languages;
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(Continued)
#11 TOPIC: (petrolatum AND decubit*)
DocType=All document types; Language=All languages;
#10 TOPIC: (petrolatum AND (pressure near/2 ulcer*))
DocType=All document types; Language=All languages;
#9 TOPIC: ((mineral near/2 oil*) AND (pressure near/2 ulcer*))
DocType=All document types; Language=All languages;
#8 TOPIC: (emollient* AND (pressure near/2 ulcer*))
DocType=All document types; Language=All languages;
#7 TOPIC: (incontinence NEAR/25 skin)
DocType=All document types; Language=All languages;
#6 TOPIC: (incontinence NEAR/25 dermatitis)
DocType=All document types; Language=All languages;
#5 #4 OR #3 OR #2 OR #1
DocType=All document types; Language=All languages;
#4 TOPIC: (((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*)))
DocType=All document types; Language=All languages;
#3 TOPIC: ((clin* SAME trial*))
DocType=All document types; Language=All languages;
#2 TOPIC: ((placebo*))
DocType=All document types; Language=All languages;
#1 TOPIC: ((random*))
DocType=All document types; Language=All languages;
F E E D B A C K
Reply to the comments made by Dr Brian Buckley, 9 June 2017
Summary
In response to feedback from Dr Brian Buckley we have made some minor amendments to the review regarding the included study
Buckley 2014. These amendments are detailed below. This did not lead to any changes in the conclusions of the review.
The feedback received from Dr Brian Buckley on 1 May 2017 is given below:
1.
The Beeckman 2016 review (says that the Philippines trial, Buckley 2014, did not report assessment procedures or on blinding (pages
14-15). Risk of bias is therefore judged in the review as high for blinding of outcome assessment (page 16 and characteristics of studies
table, which states that blinding was not possible).
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In fact, the Philippines trial report (Buckley 2014) describes assessment procedures and blinding in detail:
Randomisation and blinding
Blinding of participants and study clinical staff was not possible because the investigational products differ in appearance and odour.
However, assessment of the primary IAD severity score outcome was conducted by independent Wound, Ostomy and Continence
Nursing Certification Board (WOCNCB)-certified wound care expert assessors who were blinded to treatment allocation.
At each data collection, high-definition photographs were taken using standard operating procedures to facilitate subsequent blind
assessment of the primary outcome. Photographs included a measuring guide and were taken at least three times, both with flash and
without. … Residual ointment was meticulously removed using mineral oil so that photographs would not provide blinded assessors
with information about which ointment was used.
For determination of final trial results for the primary outcome, sets of photographs for each patient on each treatment day were assessed
by WOCNCB-certified wound care specialists in the United States (US) who were blinded to treatment allocation, independent of
both the sponsors and the investigating team and were not involved in any other aspect of the study….
2.
In the Beeckman 2016 review data are reported regarding residual IAD at the end of trial participation for one trial, but not the
Philippines trial (page 19) (Buckley 2014). In the Philippines trial (Buckley 2014), all participants entered the Philippines trial WITH
IAD, and the primary outcome of the trial was healing; therefore all participants NOT healed by definition still had IAD.
3.
In the Beeckman 2016 review it is stated that adverse events were not reported (page 20). In the Philippines trial (Buckley 2014) report
it is stated that “No adverse medical events occurred during the study.”
4.
In the Beeckman 2016 review it is stated that numbers of people with bacterial or fungal infection were not reported by included
trials (page 20). However, the occurrence of fungal infection in four participants is reported for the Philippines trial in the review’s
characteristics of studies table, as it was in the trial report (Buckley 2014).
Reply
We made the following changes for Comparison 1: Any topical skin care product versus another topical skin care product. These
changes have had no consequences for the conclusions of our review.
• Blinding of outcome assessment
We made corrections to Effects of interventions, Discussion, Figure 2; Figure 3, and Characteristics of included studies describing the
low risk of bias in the Buckley 2014 trial.
• Outcome ’Number of participants with IAD residual (i.e. not healed)
We calculated this outcome based on the frequencies reported in theBuckley 2014 trial. The resultswere added toEffects of interventions,
Summary of findings for the main comparison, and Discussion,
• Outcome ’Adverse effects (of the interventions)
We added to Effects of interventions that the Buckley 2014 trial didn’t determine any adverse effects while using Desitin and Cal-
moseptine.
• Outcome ‘Number of participants with bacterial or fungal infection’
We added to Effects of interventions that in the Buckley 2014 trial four participants were withdrawn because of fungal infections in
the IAD area.
We performed a rigorous check of the review data. Most papers were difficult to analyse because of unclear descriptions of methods,
analyses, and results, We made many efforts to perform these analyses to the best of our capabilities. Based on the latest checks, we
altered the following small elements without any consequences for the conclusions of the review:
Abstract and plain language summary:
We recalculated and corrected the total sample size (1316 versus 1295).
Comparison 1: Any topical skin care product versus another topical skin care product:
• Outcome ’Number of participants with IAD new’:
In Effects of interventions for the Anthony 1987 trial, we switched Sudocrem and standard zinc oxide. In Analysis 1.6, sample sizes
were corrected.
• Outcome ‘Number of participants with IAD completely healed’:
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In Effects of interventions for the Buckley 2014 trial, the results were changed for the results from the intention to treat analysis . In
Analysis 1.5 the labels were reversed.
• Outcome ’IAD severity’:
In Effects of interventions for the Lewis-Byers 2002 trial, we switched the sample sizes of the two groups.
Comparison 2: Any skin care procedure (method or frequency of application) versus any unstructured skin care procedure:
• Outcome ’Adverse effects (of the interventions)
In Effects of interventions for the Schoonhoven 2015 trial, we added the finding ’No Suspected Unexpected Serious Adverse Reactions
occurred’.
Tables Characteristics of included studies
• Anthony 1987: results from reduction in erythema at day 7 and at day 14 were switched between groups.
• Baatenburg de Jong 2004: mean age and BMI were switched between groups; Improvement in skin damage score in favour of
group B instead of group A; Reduction in redness, denudation: ‘A’ was changed by be ‘B’.
• Conley 2014: Braden score 16 was changed to 15.
• Lewis-Byers 2002: in participant characteristics: group A and B were switched.
Contributors
Dr Brian Buckley, trialist on an included study (Buckley 2014) contributed feedback on this review (Beeckman 2016).
Dimitri Beeckman and Nele Van Damme, two of the authors of this review, provided the response.
WH A T ’ S N E W
Date Event Description
7 August 2017 Feedback has been incorporated In response to Feedback from Mr Brian Buckley, one of the authors of the
included study Buckley 2014 minor amendments have beenmade to this review.
They are detailed under the ’Feedback’ heading in the review. These minor
amendments have not led to any changes in the conclusions of the review
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol stated that Embase would be searched as a separate database. However, as Cochrane now performs centralised
searches of Embase and uploads the results into CENTRAL, the search of CENTRAL was considered adequate to retrieve relevant
Embase records without the need to run a separate Embase search.
It was not possible to perform a funnel plot to assess reporting bias because of non-comparable designs and outcomes.
Three additional outcomes were judged to be important for patients during the course of the review process. These outcomes were:
IAD severity, number of participants with IAD completely healed, and number of participants with bacterial or fungal infection.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Topical; Amitriptyline [administration & dosage]; Dermatitis [etiology; prevention & control; ∗therapy]; Dermato-
logic Agents [∗administration & dosage]; Fecal Incontinence [∗complications]; Petrolatum [administration & dosage]; Randomized
Controlled Trials as Topic; Skin Care [methods]; Skin Cream [administration & dosage]; Soaps [administration & dosage]; Urinary
Incontinence [∗complications]; Zinc Oxide [administration & dosage]
MeSH check words
Adult; Humans
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